



CrossMark
 click for updates

Cite this: *RSC Adv.*, 2016, 6, 92073

Multifunctional mesoporous silica nanocarriers for stimuli-responsive target delivery of anticancer drugs

Yujuan Chen,^a Hui Zhang,^a Xiaoqing Cai,^a Jianbo Ji,^a Shuwang He^{*b} and Guangxi Zhai^{*a}

With the rapid development of nanotechnology, mesoporous silica nanoparticles (MSNs), as a new type of inorganic nanomaterial, have been widely used in biomedical applications especially in drug delivery systems owing to their unique physical–chemical properties such as tunable particle/pore size, high surface area and pore volume, easy surface modification, remarkable stability and biocompatibility, and high drug loading efficiency. By modifying the outer surface of MSNs with various functional groups such as polymers, co-polymers, nanoparticles, quantum dots, supermolecules, ligands, or/and using a combination with other nanomaterials, stimuli-responsive and active targeting nanosystems can be designed for targeted delivery of anticancer drugs. In this review, the recent advances in stimuli-responsive strategies involving pH-sensitive, redox-sensitive, thermo-sensitive, enzyme-sensitive, light-sensitive, magnetic-sensitive, ultrasound-sensitive, and active targeting approaches involving vascular targeting, tumor cell targeting, nuclear targeting and multistage targeting are discussed in detail. The remaining challenges and the possible future directions are also suggested.

Received 15th July 2016
 Accepted 12th September 2016

DOI: 10.1039/c6ra18062k

www.rsc.org/advances

Introduction

Cancer is a serious threat to human health and economic constraints in human life, its morbidity is increasing at an alarming rate and it is a major cause of death worldwide.¹

Conventional chemotherapy is the most common cancer treatment method based on highly potent anticancer drugs such as vinblastine, camptothecin, doxorubicin (DOX), taxol and curcuma (Cur) which can inhibit cell growth and cause subsequent apoptosis. However, the harmful side-effects due to the nonspecific uptake by normal tissues/organs and high-dose administration of therapeutic agents, non-tumor selective bio-distribution, hypersensitivity, acquisition of multidrug resistance (MDR) and toxic metabolites which can lead to cardiotoxicity and nephrotoxicity are all challenges. In addition, the poor solubility of several anticancer agents also limits the ability for intravenous delivery which is the preferred administration route for many anticancer drugs.¹ To conquer these limitations, an effective way is to encapsulate the therapeutic agents in nanocarriers with high loading efficiency, which can spatiotemporally deliver the cargos and control the release of them in a smart manner. These nanocarriers can be divided into two groups: organic (such as liposomes, dendrimers, polymeric micelle) and inorganic (such as mesoporous silica, carbon nanomaterials, graphene oxide, quantum dot, gold/silver nanoparticles, magnetic nanoparticles). Organic nanoparticles, such as liposomes, polymeric micelles are able to encapsulate/load both hydrophilic therapeutic agents and hydrophobic agents due to hydrophobic/hydrophilic interactions, chemical reactions and electrostatic interactions and so on, to protect therapeutic agents from destroying. A few conventional organic nanocarriers have been approved by FDA and applied in clinical, by contrast, most inorganic

^aDepartment of Pharmaceutics, College of Pharmacy, Shandong University, 44 Wenhua Xilu, Jinan 250012, China. E-mail: professorgxzhai@126.com; Tel: +86-531-88382015

^bDepartment of Pharmaceutical Development, Shandong Dyne Marine Biopharmaceutical Limited Corporation, 19 Lingming Beilu, Rongcheng 264300, China. E-mail: heshuwang@dynemed.com; Tel: +86-10-85869817



nanocarriers still remain in the preclinical development stage.² Inorganic nanomaterials, compared to conventional organic nanocarriers, exhibit outstanding advantages such as good biocompatibility and high thermal, mechanical and chemical stabilities under physiological conditions.³ Moreover, relatively simple chemical modifications can provide versatility of these systems and extend their application, which make them suitable for drug delivery.²

Among the different inorganic materials, MSNs are considered as one of the most promising nanomaterials for drug delivery due to its unique inherent characteristic: (I) the large surface area ($>700 \text{ m}^2 \text{ g}^{-1}$) due to MSNs unique porous, honeycomb-like frame⁴ and high pore volume ($>1 \text{ cm}^3 \text{ g}^{-1}$),⁵ which makes it possible for drug to be adsorbed and encapsulated within the pore channels at high level. (II) The smart mesoporous structure and an adjustable pore diameter (20–50 nm) which enables better control of drug loading and release kinetics.⁶ (III) At physiological pH, there is abundant negatively charged silanol groups (SiO^-) on the surface of MSNs,⁴ through interaction with SiO^- , the functionalized MSNs can be achieved by decorating with various functional groups, to control and target delivery of anticancer drug with enhanced therapeutic efficacy and reduced toxicity.^{7,8} (IV) The good biocompatibility, the research on toxicology of MSNs *in vitro* indicated that these materials are well-tolerated at dosages $<100 \mu\text{g mL}^{-1}$ ^{9,10} and toxicity could be only observed at dosage above hundreds of mg kg^{-1} *in vivo*.^{11,12} (V) When combine with magnetic and/or luminescent compounds, MSNs allow drug delivery and bioimaging simultaneously.

Due to these unique intrinsic characteristic, MSNs have been widely used to design multifunctional nanocarrier systems.

Such as immediate drug delivery systems (DDSs), sustained DDSs, stimuli-responsive controlled drug delivery systems (CDDSs), and active targeted DDSs.¹³ In this review, we mainly focus on the most rapid and significant progresses of MSNs as stimuli-responsive CDDSs and active targeted DDSs in the past three years.

Development of MSNs

Until the early 1990s, the MCM-41-type mesoporous silica was first reported and perked up the applications of MSNs in catalysis due to its large surface area and the adjustable pore size.¹⁴ In 2001, isoprofen was first successfully loaded into MCM-41 with sustained drug-releasing performance as well as the drug-loading rate up to 30%.¹⁵

Since then, the studies on MSNs increased rapidly, especially in biomedical applications such as drug delivery. The development of MSNs for drug delivery has experienced three generations.¹⁶ The properties of each generation are listed in Table 1. The rapid development of synthetic chemistry allows constructing MSNs with various structures and morphologies such as hollow nanostructures, janus MSNs, yolk shell nanorattles, organic–inorganic hybrid mesoporous silica. In addition, MSNs can conjugate with many types of functional groups due to rich reactive silanol groups on the surface of MSNs, such as targeting ligands, functional polymers/materials, and fluorescent agents. These functional groups can provide MSNs with diverse interesting functionalities including target delivery, controlled release (*e.g.*, stimuli responsive release, on-demand release), co-delivery, bioimaging, synergistic therapy, *etc.*

Table 1 The three generations of mesoporous silica based NPs for drug delivery and features properties

Generation	Features properties
Generation I: concept demonstration	<ol style="list-style-type: none"> 1. Evaluations of the sustained releasing performances of various loaded cargos <i>in vitro</i> 2. Large particle sizes, irregular morphologies and severe aggregations 3. Limited cell-level evaluations and <i>in vivo</i> applications
Generation II: standard evaluation	<ol style="list-style-type: none"> 1. Standard MSNs-based nanosystems and systematic <i>in vitro</i> and <i>in vivo</i> evaluations 2. Uniform spherical morphology, tunable pore/particle sizes and compositions 3. MSNs with hollow nanostructures (HMSNs) enhance the drug-loading capacity of the carriers
Generation III: multifunctionalization	<ol style="list-style-type: none"> 1. Diverse functionalities, such as targeted delivery, co-delivery, on-demand releasing, synergistic therapy, overcoming the multidrug resistance (MDR) of cancer cells, theranostic, bioimaging 2. The surface of MSNs can be modified with a variety of biocompatible materials which possess unique physical–chemical properties or/and biological recognition ligands to control drug release under stimulation and promote the targeted transport, even co-delivery different therapeutic agent 3. The combine of mesoporous silica and magnetic nanoparticles, quantum dots, gold/silver nanoparticle, upconverting nanoparticles, photothermal conversion material, fluorescence material broaden the versatility of silica based nanocarriers 4. Janus MSNs, yolk shell nanorattles and organic–inorganic hybrid mesoporous silica further enhance the drug-loading capacity of the carriers and broaden the types of loading cargo

Stimuli-responsive MSNs

Stimuli-responsive MSNs only release the cargos in the targeted cancer sites upon triggering by intratumoral stimuli (pH, redox, enzyme, temperature) or exogenous stimuli (magnetic field, ultrasound, light) with nearly no premature drug release (Fig. 1). The stimuli-responsive nanosystems based on MSNs are shown in Tables 2 (pH) and 3. The schematic diagram of stimuli-responsive mechanism is shown in Fig. 2. Stimuli-responsive MSNs have been regarded as promising approach to improve the therapeutic effect of anticancer agent and simultaneously reduce the undesirable side effects to normal cells.

Intratumoral stimuli-sensitive MSNs

Various kinds of tumor tissues share similar microenvironment distinct from normal ones, such as leaky vasculatures, acidic and hypoxic environments, high redox potential, increased level of cancer-associated enzymes and higher local temperature. Based on these, stimuli-sensitive delivery system can be designed to respond to the tumor microenvironment.

pH-Responsive MSNs

Among the various stimuli-sensitive DDSs, pH-responsive CDDSs have been widely researched since the human body exhibits variations in pH. The pH value approximately 7.4 in extracellular of normal tissues and blood, while between 6.0 and 7.0 in tumor microenvironment, which is mainly caused by high level of CO₂ and high glycolysis rate.¹⁷ The pH value will decrease further inside cancer cell such as endosomes (pH = 5.5–6.0) and lysosomes (pH = 4.5–5.0). Therefore, we can combine the unusual

pH gradients with the advantages of MSNs to design pH-responsive nanosystems which can control the release of drug molecules under certain pH conditions. The pH-responsive nanosystems based on MSNs are shown in Table 2.

pH-Sensitive linkers such as hydrazine bond, acetal bond, boronate ester bond and ester bond that can be cleaved under acidic pH value, thus providing the possibilities for designing pH-responsive MSNs.

A multifunctional envelope-type DDS based on upconverting nanoparticle-capped mesoporous silica (MS) *via* pH-sensitive linkers was reported by Chen *et al.*¹⁹ In this study, the gatekeeper (S-NPs), upconverting nanoparticle doped with ultra-small lanthanide (NaGdF₄:Yb/Tm@NaGdF₄), was grafted onto the orifices of MS with the acid-labile acetals. DOX as model drug was trapped in the pores. At acidic pH, the S-NPs caps were removed due to hydrolysis of acetal group. DOX loaded nanocomposite could accumulate in tumor through enhanced permeation and retention (EPR) effect after intravenous injection into the murine model. DOX was rapidly released in the acidic environment of lysosomes and endosomes, which enhanced the therapeutic efficacy by remarkable inhibition of tumor growth, and the treated mice survived over 30 days without any obviously visible tumor growth. In addition, the encapsulation of gadolinium makes the nanocomposite a promising T1-MRI contrast agent with contrast enhanced MRI performance. Importantly, the nanocomposites are biocompatible and could be metabolized and degraded into nearly nontoxic products within a few days.

The supramolecular nanovalve for controlling drug release, is composed of an immobilized stalk molecule connected to the silica matrix *via* covalent interaction and a movable cyclic molecule as the gatekeeper encircling the stalk non-covalently. More importantly, the binding process of cyclic gatekeeper/




Fig. 1 Stimuli-responsive drug delivery based on MSNs in cancer therapy.

Table 2 pH-Responsive nanosystems based on MSNs

Type	Material	pH-Responsive mechanism	Ref.
Acid cleavable linker/bond	Gold NP-acetal linker-MS	Acetal linker	18
	Lanthanide doped NP-acetal bond-MS	Acetal bond	19
	Fe ₃ O ₄ NP-boronate ester bond-MSNs	Boronate ester bond	20
	Poly(<i>N</i> -succinimidyl acrylate)-acetal linker-MS	Acetal linker	21
	MSN-hydrazone-Dox	Hydrazine	22
	DOX@PAA-ACL-MSN	ACL	23
	Au NPs-DNA-MSNs	DNA	24
Polymer gatekeepers	DOX@MSNs-gelatin	Gelatin	25
	DOX@MSNs-chitosan	Chitosan	26
	DOX@MSNs-PVP-PEG	PVP	27
	DOX@MSNs-PLGA	PLGA	28
	PAH/PSS MSNs	PAH/PSS polyelectrolyte multilayers	29
	Alginate/chitosan-NH ₂ -MSNs	Alginate/chitosan multilayers	30
	Chitosan/dialdehyde starch-MSNs	Chitosan/dialdehyde starch polyelectrolyte multilayers	31
	PAH-cit/APTES-MSNs	Charge-reversal polymer PAH-cit	32
	Cur@PAMAM-MSNs	PAMAM-	33
	PDEAEMA-MSNs	PDEAEMA	34
	DOX@PAA-MSNs	PAA	35
	DOX@PPEMA/PEG-MSNs	PPEMA	36
	i-motif DNA-MSNs	i-motif DNA	37
Supramolecular-nanovalves	β-Cyclodextrin caps-aromatic amines stalks-MSNs	Aromatic amines stalks	38 and 39
	α-Cyclodextrin- <i>p</i> -anisidino stalks-MCM-41	<i>p</i> -Anisidino stalks	40
	cucurbit(6)uril-trisammonium stalks-MSNs	Trisammonium stalks	41
Acid decomposable gatekeepers	ZnO@MSN	ZnO	42
	DOX-Si-MP-cap	pH-Tunable calcium phosphate	43
	LDHs-MSNs	LDHs	44

stalk is reversible and the supramolecular gatekeeper can be switched under certain stimuli (pH, light, redox potential, temperature), causing large amplitude movement of the gatekeeper, which in turn leads to the blocked pore open.⁴⁵

Based on the noncovalent interactions between cyclic molecule caps and immobilized amine stalks, Ling *et al.*⁴⁶ successfully constructed a pH-responsive nanosystem in view of CD capped MSN that could control the release of cargo. With DOX as model drug and β-CD as gatekeeper, this constructed nanosystem showed a good pH-sensitive release property. The cumulative release within 4 h was 0.7% at pH 7.4 and 3.6% at pH 6.5, because the tight bind between hydrophobic *p*-anisidine stalks and CD caps blocked the nanopores limited the release of DOX. When at pH 5.0, the cumulative release increased significantly to 84.2% because the binding between *p*-anisidine stalks and β-CD decreased and forced the removal of the CD caps, then the cargo released by diffusion. In addition, they investigated the *p*-anisidine stalks density and type of CD which were critical factors impacting the pH inducing drug release. Result showed that the too high or too low density of the grafted *p*-anisidine stalk could lead to poor drug release, and the optimal stalk density was ~8.7 stalks per nm². Different types of CD capes (α-CD and β-CD) were investigated and results showed that the complex of *p*-anisidine stalk with β-CD had an excellent pH-sensitive release capability for its largest changed formation constant (ΔK_f). Furthermore, the mechanism of pH-sensitivity between CD and *p*-anisidine stalk was investigated, under

neutral or acidic media, the binding process of *p*-anisidine/α-CD was significantly enthalpy-driven with the main driving force of van der Waals forces and hydrogen bonding. While the complexation process between *p*-anisidine and β-CD was entropy-driven with strong hydrophobic interaction under neutral environment, but weak hydrogen bonding existed under acidic pH. In short, both the stalk density and type of CD could significantly affect the pH-sensitive release capability.

pH-Sensitive polymer shell contains functional groups with acid/base properties. Thus, the polymer shell, such as poly(2-vinylpyridine) PVP,²⁷ self-fluorescent agents PAMAM (polyamidoamine) dendrimers,³³ poly(2-(diethylamino)ethyl-methacrylate) PDEAEMA,³⁴ poly(2-(pentamethyleneimino)ethyl-methacrylate) (PPEMA)³⁶ and i-motif DNA,³⁷ can undergo strong conformational structure transformation with the variation of external pH because of strong hydrophilic change, chargeability change, solubility change.³⁵ The polymer shell also can be easily modified with various targeting ligands to acquire active target delivery, simultaneously.

Containing repeating charged groups, polyelectrolytes that can be either covalently bonded or electrostatically adsorbed to the surface of MSNs and undergo form transition along with the changes of pH values, which have been also utilized to design pH-responsive release system.

Poly(allylamine)-citric anhydride (PAH-cit) is a pH responsive charge-reversal polymer, whereby the charge can be readily converted from negative to positive through side-chain

Table 3 The stimuli-responsive nanosystems based on MSNs

Type	Material	Mechanism
Redox responsive	CdS ⁵⁰ Au ⁵¹ Fe ₃ O ₄ ⁵² Poly(propyleneimine) dendrimers ⁸ PEG ^{13,53,54} heparin ⁵⁵ peptides ⁵⁷ polyethylenimine (PEI) ⁵⁶ cyclodextrin ^{58,59} PDS ⁶² cytochrome c ⁶⁰ PEG- PCL ⁶¹	Inorganic NPs–disulfide bonds–MSNs Organic molecules–disulfide bonds–MSNs
	mPEG@6-MP@CMS ⁵³ HA@6-MP@CMS ⁶³ MSN@MnO ₂ ⁶⁴	Thiolated drug–disulfide bonds–MSNs
Enzymes responsive	MSN–GFLGR7–RGDS/ α -CD ⁶⁵ DNA ⁶⁸ HA ⁶⁹ gelatin ^{70,71} cellulose ⁷² galacto- oligosaccharides ⁷³	Glutathione degradable gatekeepers Protease-sensitive crosslinker Enzyme degradable polymer
Temperature responsive	Poly(ethyleneoxide- <i>b</i> - <i>N</i> -vinylcaprolactam), ⁷⁹ zwitterionic sulfobetaine copolymers, ⁸⁰ paraffins, ⁸¹ supramolecules rotaxane ⁸² copolymer–lipid bilayers ⁸³ DNA ^{84,85} peptide sequences ^{86,87}	Thermo sensitive polymers
Magnetic responsive	Poly(<i>N</i> -isopropylacrylamide/ <i>N</i> - hydroxymethylacrylamide), ⁹⁸ poly(ethyleneimine)- <i>b</i> -poly(<i>N</i> - isopropylacrylamide), ⁸⁹ lipid bilayer, ¹⁰⁴ pseudorotaxanes ¹⁰⁵ mNPs + DNA + MSNs ¹⁰³ Azo-PEG@Fe ₃ O ₄ @SiO ₂ ⁹⁶ SPION@MSN-DA ⁹⁵	Thermo sensitive bio-molecules Heat produced by AFM + thermo-sensitive gatekeeper
		Heat produced by AFM + thermally unstable chemical linkers Heat produced by AFM + thermally reversible cycloreversion reaction
Ultrasound responsive	MSNC@Au–PFH–PEG ¹¹¹ p(MEO2MA)- <i>co</i> -THPMA ¹¹⁶ Fc–CONH–MS ¹¹⁷	Ultrasound sensitive material + cavitation Ultrasound-cleavable moieties Ultrasound sensitive of ferrocene derivative
Light responsive UV-Vis	β -CD and/or Py- β -CD–azobenzene stalks– MSNs ¹¹⁸ α -CD–azobenzene stalks–MSNs ¹¹⁹ Thymine derivatives–MSNs ¹²⁰ <i>o</i> -nitrobenzyl ester moiety–MSNs ¹²¹ poly(<i>N</i> - isopropylacrylamide- <i>co</i> -2-nitrobenzyl acrylate)– MSNs ¹²²	The isomerized of azobenzene group from <i>cis</i> to <i>trans</i>
		Photoresponsive polymers gatekeeper
NIR	7-Amino-coumarin derivative (CD)–MSNs, ¹²³ S- coordinated Ru(bpy) ₂ (PPh ₃)-moieties–MSNs, ¹²⁴ TUNA–MSNs ¹²⁵	Photoresponsive linkers
	DNA–Au@MSNs ⁹¹ DNA–Cu _{1.8} S@mSiO ₂ ⁹² 1-Tetradecanol-GNR@MSNs ¹²⁷ sulfonatocalix[4]arene–AuNR@MSN ¹²⁸ Au–nanocage@mSiO ₂ @PNIPAM ¹²⁹ CuS@mSiO ₂ –PEG ¹³⁰ SWNT@MS–PEG ¹³¹ UCNP@mSiO ₂ –Ru ¹³²	NIR-absorbing materials + thermal-responsive materials

hydrolysis upon exposure to acid solutions. Using this property, Zhang *et al.*,³² firstly developed a PAH–cit coated MSNs (PAH–cit/APTES MSNs) and the MSNs was applied to devise an *in situ* monitoring system of intracellular pH-responsive DDSs for the treatment of malignant cells. APTES ((3-aminopropyl)triethoxysilane) was modified onto MSNs to obtain amino-functionalized MSNs, then, through electrostatic interactions, PAH–cit was bonded onto the inner and outer surfaces of amino-functionalized MSNs (APTES MSNs). In acidic environments, the loaded DOX was steadily released from the MSNs as a result of strong electrostatic repulsion forces among the positively charged MSNs (APTES–MSNs), PAH and DOX. The

result showed that the constructed nanocomposite (PAH–cit/APTES–MSNs) could effectively deliver and release DOX to the nucleus of HeLa (human cervical carcinoma) cells.

Polyelectrolyte multilayers (PEM) are sensitive to various specific physical and chemical conditions of the surrounding medium based on its special properties and structure. In particular, the pH can largely influence the state of the inter-polyelectrolyte complex. Based on this, pH-sensitive drug release systems *via* electrostatic interaction have been developed in contribution to layer-by-layer assembly of PEM onto MSNs surface, such as poly(allylamine hydrochloride) (PAH)/poly(styrene sulfonate) (PSS),²⁹ alginate/chitosan³⁰ and chitosan




Fig. 2 The schematic diagram of stimuli-responsive mechanism.

(CHI)/dialdehyde starch (DAS).³¹ The biocompatible polyelectrolyte multilayers functionalized MSNs have stupendous potential to developed efficient and safe drug delivery system.

Some acidic-decomposable materials such as ZnO quantum dots (QDs),⁴² calcium phosphate (CaP),⁴³ layered double hydroxides (LDHs) which include the positively charged brucite-type layers and exchangeable interlayer anions,⁴⁴ have recently been reported as gatekeepers to design pH-sensitive DDSs.

ZnO QDs are stable at pH 7.4, but when the pH is less than 5.5, ZnO QDs immediately dissociate into Zn^{2+} ions which induce the generation of ROS and the ROS can involve lipid peroxidation and damage of DNA. Based on this, Zhang and coworkers⁴² developed a dual pH-sensitive DDS ZnO@MSN. In this system, cell-penetrating peptide decalysine sequence (K10) covalently covered MSNs *via* acid-labile β -carboxylic amides and the peptide can also enhance endosomes/lysosome escape capability. After this, ZnO QDs capped MSNs *via* electrostatic interaction to achieve a synergistic antitumor effect. At pH 7.4, almost no DOX released from the ZnO@MSN DDS after 48 h, however, DOX was released rapidly at pH 5.0 from the system, about 34%, 86% of DOX was released within 12 h, 48 h, respectively, because the dissociation of ZnO QDs and the hydrolysis of acid-labile amides led to the uncap of MSNs, which confirmed that ZnO@MSN had great sensitivity to the pH signal of endosomal environment and obtained intracellular drug release. In addition, compared to free DOX, the DOX-loaded ZnO@MSN showed higher cytotoxicity with IC_{50} of $50 \mu\text{g mL}^{-1}$.

An innovative strategy to obtain pH-responsive DDSs is using janus nanoparticles. For example, Shao *et al.*⁴⁷ reported a novel janus nanoparticles (Ag-MSNs) with a silver nanosphere head and a mesoporous silica ordered mesostructure body. Within 24 h, more than 40% of DOX released in pH 5.5, while less 5% was released at pH 7.4 due to the protonation and solubility of DOX in acidic environments.

Redox-responsive MSNs

Glutathione (GSH) is an important antioxidant in the human body, protecting cellular components from damage caused by

reactive oxygen species (ROS). In particular, the GSH concentration in the intracellular environment is about 10^3 folds higher than that in the extracellular matrix. Furthermore, the intracellular GSH concentrations in most tumor cells are at least 4-times higher than those in normal cells.⁴⁸ Therefore, GSH can be a potential trigger for drug release within cancer cells. Given the fact that disulfide bonds are sensitive to GSH reductant, smart designs incorporating disulfide S-S linkages into nanoparticles can lead to redox-triggered release systems.⁴⁹ Inorganic nanoparticles such as CdS,⁵⁰ Au,⁵¹ Fe_3O_4 ⁵² and organic molecules such as poly(propyleneimine) dendrimers,⁸ PEG,^{13,53,54} heparin,⁵⁵ polyethylenimine (PEI),⁵⁶ peptides,⁵⁷ cyclodextrin,^{58,59} cytochrome c,⁶⁰ poly(ethylene glycol)-*b*-poly(ϵ -caprolactone) (PEG-PCL),⁶¹ can be chemically attached on the MSN surface as biocompatible gatekeepers to control drug release by using GSH-sensitive linkers. When the nanocarrier reaches the intracellular sites, the existence of increased amounts of reductive species can produce the rupture of the disulfide bonds and open the pores.

Palanikumar *et al.*⁶² reported an active target and redox-responsive MSNs through one-pot synthesis, which could load DOX or cisplatin or DOX and cisplatin with high efficiency at 44, 33 wt% and 25% for DOX and 14% for cisplatin, respectively. Self-crosslinkable random copolymer containing biocompatible pyridine disulfide hydrochloride (PDS) and PEG side chains noncovalently end-capped MSN without multiple chemical modifications. PDS has multiple functions including wrapping the negatively charged MSNs *via* temporarily positive charge, stabilizing polymer-MSNs shell as a crosslinker and connecting the targeting ligand (cyclic (Arg-Gly-Asp-D-Phe-Cys) (cRGDfC), an integrin-targeting ligand) through its functional group. Intracellular reducing agents such as glutathione (GSH) can lead to the cleavage of the wrapped polymer and induce the release of cargo in a concentration-dependent manner.

A new strategy is connecting the thiol-containing/thiolated therapeutic agent to the inside and outside of MSNs *via* cleavable disulfide bonds to design redox-responsive DDS. Zhao *et al.*^{53,63} designed a redox-responsive DDS based on 6-mercapto-purine (6-MP)-conjugated colloidal mesoporous silica (CMS) *via* disulfide bonds. Hydrophilic polymers mPEG modified the outside of MSNs to improve the biocompatibility and dispersibility of CMS by reducing hemolysis and protein adsorption,⁵³ and hyaluronic acid (HA) as a targeting ligand was grafted on CMS surface through disulfide bonds which also increased the biocompatibility and stability of CMS under physiological conditions.⁶³ CMS was prepared through a co-condensation method, involving the simultaneous condensation of TEOS and MPTMS, to obtain a homogeneous distribution of mercapto groups on the internal and external surface of the CMS carrier. *In vitro* release studies demonstrated that the CMS possessed the great redox-responsive drug release capability. For the CMS-SSMP@mPEG,⁵³ the cumulative release of 6-MP was less than 3% without GSH, while more than 70% of loaded 6-MP was released within 2 h in the existence of 3 mM GSH. For the CMS-SS-MP/oHA,⁶³ the cumulative release of 6-MP within 2 h was less than 3% without GSH, while more than 80% for that in the existence of 3 mM GSH.

Another new strategy to design redox-responsive DDS is capping outside of MSNs with glutathione degradable gatekeepers. Yang *et al.*⁶⁴ have demonstrated a new type of redox-responsive DDS by employing glutathione degradable MnO₂ as capping to block the pore of MSNs. In the presence of GSH molecules, the capped MnO₂ nanostructure dissociated into Mn²⁺ *via* redox reaction, which opened the blocked pores and resulted in the release of the entrapped drugs.

Enzymes-responsive MSNs

Recently, due to mild reaction conditions, high specificity, and less damage to body tissues, enzyme reactions have received widespread attention. More importantly, many specific enzymes show a high level of expression in tumor tissues and cancer cells but no or relatively low level of expression in healthy tissues or normal cells.⁶⁵ Endogenous enzymes in tumor tissues and cancer cell have used as stimuli to trigger drug release.

To obtain enzymes-responsive release, one strategy is coating MSNs with gatekeepers containing protease-sensitive sequences or enzyme-sensitive linkers. Cathepsin B, which overexpressed in late endosomes and lysosomes of cancer cells, could selectively hydrolyze specific peptide sequences.^{65–67} Cheng *et al.*⁶⁵ described an enzyme-induced and tumor-targeted mesoporous silica nanocarrier which was capable of releasing therapeutic drugs in response to increased levels of cathepsin B. In the nanocarrier, the alkoxy silane chain and α -cyclodextrin (α -CD) formed rotaxane structure and anchored onto the pore of MSNs as gatekeeper, subsequently modified by azido-GFLGR7–RGDS which included a cell-penetrating peptide with seven arginine (R7) sequence, a cathepsin B-cleavable peptide of Gly–Phe–Leu–Gly (GFLG) as crosslinker and a tumor-targeting peptide of Arg–Gly–Asp–Ser (RGDS) to stabilize the gatekeeper. The *in vitro* release results indicated that in the presence of cathepsin B (20 U), 60% and 80% of loaded DOX could be released from the DOX@MSN–GFLGR7–RGDS/ α -CD nanoparticles in pH 7.4 and pH 5.0 PBS buffer within 24 h, respectively. By contrast, in the absence of cathepsin B, due to the protection of the gatekeeper on the surface of the MSNs, less than 10% of loaded DOX was released during the same period. Furthermore, *in vitro* cellular experiments indicated that this nanocarrier had high growth inhibition rate toward α v β 3-positive HeLa cancerous cells.

Biopolymers such as single-stranded DNA,⁶⁸ HA,⁶⁹ gelatin^{70,71} and other polymers such as cellulose,⁷² galactooligosaccharides⁷³ can be grafted on MSN surface, acting as enzyme-responsive nanovalves and hampering the drug diffusion until certain hydrolytic enzymes which are capable of decomposing these polymers are present. Matrix metalloproteinases (MMPs) are up-regulated in most human cancer and they are involved in tumor invasiveness, metastasis, and angiogenesis.⁷⁴ Based on this, Zou and coworkers⁷¹ conjugated the FA–MSN with MMP2-degradable gelatin to develop a smart mesoporous silica nanocarrier (PGFMSN) which showed MMP2-triggered release and FA modified tumor targeting. After functionalizing MSN with target ligand FA, gelatin layer

was decorated onto FA–MSN as gatekeeper to control the release of drug and protect the target ligand. In order to prolong blood circulation lifetime, PEG was further introduced to obtain PGFMSN. In these nanosystems, DOX was effectively loaded in PGFMSN with the loading amount as high as 74.3 mmol g^{−1} SiO₂. The *in vitro* release results indicated that PGFMSN exhibited MMP-2 concentration-dependent release profiles *via* MMP2-triggered hydrolyzation of the gelatin layer with approximately 7.2%, 19.1%, 43.7% and 75.3% of loaded DOX released at MMP2 concentration of 0, 1.25, 2.5, 5.0 mg mL^{−1} within 600 min. Owing to the introduction of gelatin, FA and PEG, PGFMSN can specifically target cancer cells by up-regulated extracellular MMP2 and FA receptor, exhibiting enhanced cancer cell internalization. Most importantly, the *in vivo* therapeutic study indicated that compared with free DOX, non-targeted nanoparticles and non-PEG nanoparticles, DOX@PGFMSN exhibited the better therapeutic efficacy.

Temperature-responsive MSNs

It has been revealed that the local temperature in many tumors, inflamed or infected tissue is higher than normal body temperature by 4–5 °C. Motivated by this, researchers graft temperature-sensitive gatekeepers on MSN surface to retain their cargo at normal body temperature (~37 °C), and rapidly release at higher temperature (~40–42 °C) of heated tumor site, which can prolong blood-circulation lifetime of the cargo and avoid washout from the tumor. A common temperature-responsive gatekeeper is thermo-sensitive polymer based on poly-*N*-isopropylacrylamide (PNIPAM) and its derivatives.¹¹ PNIPAM can undergo a transition from hydrophilic to hydrophobic at “lower critical solution temperature” (LCST) of about 32 °C.⁷⁵ Below the LCST, PNIPAM chains are hydrophilic and extended, preventing the release of the loaded drugs, when temperature is above the LCST, PNIPAM chains are dehydrated and collapsed, leading to the pore open and the release of the cargo.¹¹

The LCST of pure PNIPAM is around 32 °C that is not suitable for biomedical applications. Increasing the LCST to physiological temperature can be achieved by introducing hydrophilic monomers into the polymer composition, such as acrylamide,⁷⁶ *N*-isopropylmethacrylamide (the LCST increased to ~37 °C).^{77,78} Other thermo-sensitive polymers such as poly(ethyleneoxide-*b*-*N*-vinylcaprolactam),⁷⁹ biocompatible zwitterionic sulfobetaine copolymers,⁸⁰ paraffins,⁸¹ supramolecules rotaxane⁸² or copolymer–lipid bilayers⁸³ have been also reported. Besides these abiotic thermo-sensitive polymers, some bio-molecules have also been utilized, such as double-stranded DNA (temperature above its melting point could induce the melting of ds-DNA),⁸⁴ reversible single-stranded DNA⁸⁵ (as the DNA gatekeeper which could be adsorbed outside of the silica shell *via* electrostatic interaction and destroyed at high temperature, leading to the release of loaded cargo molecules from the nanocarrier), peptide sequences^{86,87} (present the disassemble processes or α -helix-to-disordered transformation at specific temperature).

Another strategy was based on the combination of magnetic^{88–90} or photothermal^{91,92} materials with thermo-sensitive polymers to reach temperature-triggered drug release.

Exogenous stimuli-sensitive MSNs

In this section, stimuli-responsive DDSs that take advantage of externally applied stimuli, including magnetic fields, ultrasounds and light, were discussed.

Magnetic-responsive MSNs

Magnetic particles could be heated up under alternating magnetic field (MF), or be guided to the tumor tissue under a locally applied external MF. Therefore, researchers take advantage of magnetic field and designed magnetic-responsive DDSs through combining MSNs with magnetic particles. Biocompatible superparamagnetic iron oxide nanoparticles (SPION) are the most widely employed magnetic particles. Under an extracorporeal permanent MF focusing on the biological target, injected magnetic responsive nanocarriers can be guided to the target site. The temperature will rise when an alternating magnetic field (AMF) is applied or permanent and alternating MF is alternately used. These magnetic particles transform magnetic energy into heat following two mechanisms, Brownian fluctuations caused by the rapid rotation of the nuclei and Néel fluctuations incited by the spontaneous reorientation of the magnetic moment of particle, which are consequence of the rotation of the magnetic moments.^{93,94} The heat produced by an AMF can be used to achieve on demand pulsatile drug release. By adjusting the intensity and location of the MF, the accumulation of nanocarriers and the release of loaded drug can be controlled, and harmful side effects on

normal tissues can be avoided. Therefore, the combination of magnetic nanoparticles (mNPs) and MSNs with high target specificity, loading capacity and magnetic properties constitute promising DDSs to target and control the drug release.

The different possible structures of the combination between MSNs and magnetic nanoparticles (mNPs) can be summarized into four categories (Fig. 3): (I) core-shell structure covering mNPs core with mesoporous silica shell.^{95–98} The outer mesoporous silica shell provides pore volume and enough surface area for drug store and release, stimuli-responsive gatekeepers placed on the pore outlets controlled the release under an external magnetic field. (II) Rattle-type hollow structure composing of mNPs core and mesoporous silica shell.^{99,100} Research showed that the saturation magnetization value of rattle-type hollow structure (35.7 emu g^{-1}) is significantly higher than that of the corresponding core-shell structure with an intact middle silica layer (28.8 emu g^{-1}) due to the removal of the in-between silica layer. Furthermore, pore volume and surface area of the rattle-type structure are calculated to be $0.58 \text{ cm}^3 \text{ g}^{-1}$ and $435 \text{ m}^2 \text{ g}^{-1}$, respectively, which are obviously higher than the sample with an intact middle silica layer ($274 \text{ m}^2 \text{ g}^{-1}$ and $0.38 \text{ cm}^3 \text{ g}^{-1}$).¹⁰⁰ Therefore, the rattle-type structure is more suitable for targeting drug release. (III) Embedded structure encapsulating mNPs in mesoporous silica nanospheres;^{89,101} (IV) mesoporous silica nanoparticles being capped with mNPs.^{102,103} mNPs can be immobilized onto the surface of MSNs surface *via* chemical linkers or polymer.

As mentioned above, there will be a temperature increase when magnetic-responsive MSNs were under an AMF. Therefore, temperature-responsive gatekeepers (such as DNA, thermo-sensitive polymer) can be used to induce pore opening




Fig. 3 The four possibilities structures of the combination between mesoporous silica nanoparticles and magnetic nanoparticles (mNPs).

accompanied by temperature increase. Thermosensitive polymers like poly(*N*-isopropylacrylamide/*N*-hydroxymethylacrylamide),⁹⁸ poly(ethyleneimine)-*b*-poly(*N*-isopropylacrylamide),⁸⁹ lipid bilayer¹⁰⁴ and temperature sensitive pseudorotaxanes¹⁰⁵ act as thermosensitive nanovalves have been reported. At high temperature achieved by applying an external magnetic field, these temperature-responsive gatekeepers present structural changes, permeability increasing, molecular nanocap disassemble. mNPs or polymers can be placed onto the surface of MSN *via* thermally unstable chemical linkers like single-stranded DNA with a melting temperature of 47 °C¹⁰³ or unstable covalent bond azo bond.⁹⁶ Zink and co-worker⁹⁶ firstly reported a core-shell Fe₃O₄@SiO₂ nanocarrier coated with thermodegradable azo-functionalised PEG. The thermally decompose capability of the azo compounds makes them widely used as thermal initiators *via* initiate radical polymerizations. Azo-PEG can be broken at high temperature caused by a high frequency oscillating MF, leading to the release of loaded drug, while restricting cargo in mesopores at body temperature. This strategy exhibits no fibroblast cytotoxicity, indicating its safety and no damage to the surrounding tissues, because the external MF produces locally heat within a nanoscopic volume.

[2 + 4] cycloaddition reaction (Diels Alder reaction) and cycloreversion reaction (retro-Diels Alder reaction) of furan derivatives with maleimide derivatives can be carried out at mild temperature, especially, cycloreversion reaction can proceed at conventional heating or heating triggered by superparamagnetic. Based on this, Rühle and associate⁹⁵ constructed a novel magnetic-responsive DDS (SPION@MSN-DA) with thermoresponsive snaptop as gatekeeper by fixing the adamantane group onto maleimide functionalized SPION@MSN (SPION core-mesoporous silica shell) *via* a thermally reversible [2 + 4] cycloaddition of a furan-modified linker. When under external AMF, cycloreversion reaction could be carried out, leading to cap detach from MSN, pore open and loaded cargo release.

Besides superparamagnetic iron oxide NPs, superparamagnetic manganese ferrite nanoparticles¹⁰⁶ and zinc-doped iron oxide nanocrystals^{105,107} combined with MSNs have been reported to produce novel magnetic responsive drug delivery systems.

Ultrasound-responsive MSNs

Among possible external stimuli, ultrasounds (US) as an effective external trigger can be used to control drug release spatio-temporally. US is appealing due to its non-invasiveness or minimally invasiveness, without ionizing radiations, cost effectiveness and easy control of tissue penetration depth by tuning the frequency, cycles and exposure time.⁹³ High-frequency US can penetrate deeply into the body with focused beams, which allows local therapy avoiding adverse side effects to healthy tissues. Moreover, the US can not only trigger drug release from nanocarriers but also enhance drug-loaded nanoparticle extravasation through blood capillaries, which increase cell membrane permeation and even induce an immune response against tumors.^{108,109}

Several physical effects will occur when an US wave propagates through body tissue, so it can be utilized as trigger to design ultrasound-responsive DDSs. These physical effects include cavitation, local higher temperature, simple pressure variation and acoustic fluid streaming. An ideal ultrasound-responsive DDSs typically involves ultrasound sensitive material to respond to one or more of these physical effects.¹¹⁰

Wang and coworkers¹¹¹ synthesized an Au NPs-capped, perfluorohexane (PFH)-encapsulated and PEGylated mesoporous silica nanocapsules-based enhancement agents (MAPP). Hydrophobic pyrene as model drug was loaded into MAPP (pyr-MAPP) to verify the effect of US on inducing drug release behavior of MAPP. Before US irradiation, nearly no pyrene was released, by contrast, under/after ultrasound irradiation, a plenty of smaller-sized phase-changed PFH micro bubbles in MAPP solution were generated, subsequently further swelled and merged into larger microbubbles which could enhance the release of pyrene. This indicated that the nanosized inorganic MAPP possessed excellent US sensitivity, and the loaded drug release could be trigger-controlled and enhanced *via* external US.

US waves can induce thermal and/or mechanical effects that trigger the loaded drug release from nanocarriers. Moreover, the advances in sonochemistry have shown that ultrasound-induced chemical reactions can differ from those carried out by bulk heating, implying mechanical or thermal effects at the nanoscale.¹¹² US irradiation can also cleave certain chemical bonds, so-called mechanophores.^{113,114} This strategy can be exploited in the design of responsive nanoparticles with ultrasound-labile moieties. 2-Tetrahydropyranyl methacrylate (THPMA) can undergo a phase transformation from hydrophobic to hydrophilic by US irradiation. THPMA is a hydrophobic monomer bearing a labile acetal group that can be cleaved by US to yield hydrophilic methacrylic acid (MAA).^{113,115} Based on this, Paris *et al.*¹¹⁶ developed a new ultrasound-responsive system with MSNs as carriers and dual-responsive copolymers composed of a thermoresponsive poly(2-(2-methoxyethoxy)ethyl-methacrylate) (p(MEO2MA)) and THPMA (MEO2MA : THPMA = 90 : 10) as nanogates sensitive to ultrasounds. The thermal response can be used to load and retain the cargo, and the US sensitivity can induce the release of cargo at physiological temperature. Copolymer p(MEO2MA)-*co*-THPMA bearing US-cleavable hydrophobic tetrahydropyranyl moieties, presents a LCST below physiological temperature. At 4 °C, the polymer is in its coil-like conformation, allowing the cargo to be loaded in the mesopores. When the temperature is increased to physiological temperature, the copolymer changes to a collapsed state and the nanogates are closed retaining the cargo into the pores. Upon US irradiation, the hydrophobic tetrahydropyranyl groups in the polymer backbone were cleaved, leading to hydrophilic methacrylate and increasing the LCST over 37 °C. This induced a change in conformation of the polymer to coil-like, opening the gates of the mesopores of the MSNs and allowing the release of entrapped cargo. These hybrid nanoparticles were no cytotoxic and could also be endocytosed by LNCaP cells, retaining their ultrasound-responsive capability because they could release the cargo inside the cells upon US

irradiation. When loaded with DOX, the hybrid MSNs only induced cell death when exposed to ultrasound. Dating back to 2007, Kwon and coworkers¹¹⁷ first designed a newly ultrasound-responsive system Fc-CONH-MS by grafting a ferrocene derivative including carboxylic acid group at both ends onto the outside of amino-functionalized MSN. Upon ultrasound irradiation, the ferrocene derivatives could be easily broken up by local hyperthermia or the reaction of oxidized species, allowing the entrapped cargo to be released.

Ultrasound-targeted DDS based on MSNs has achieved some progress, but still in its infancy, need further study.

Light-responsive MSNs

Among various external stimuli, light is chosen as a trigger on account of its rapid activation, low invasiveness and the possibility of remote spatiotemporal control, which has been widely applied, especially in drug delivery systems. In the past few years, a large variety of light-responsive systems have been designed to obtain on-demand drug release in response to illumination of a specific wavelength (in the ultraviolet, visible or near-infrared (NIR) regions).

Under UV irradiation, the azobenzene group and/or its derivatives can undergo isomerization from a planar *trans* form to a non-planar *cis* form in surrounding aqueous medium. The isomerization from *cis* to *trans* via illumination in the visible region enables photo-regulated control of drug release.^{118,119} Zink and coworkers designed a light-operated nanosystem with an immobilized azobenzene-containing stalk molecule connected to MSNs, light-operated dissociation movable β -CD and/or Py- β -CD cyclic molecule threaded onto the azobenzene-containing stalks, acting as gatekeeper. Without the irradiation of 351 nm light, movable cyclic molecule could bind to *trans*-azobenzene units to form the pseudorotaxanes, limiting release of the cargo through closing the nanopores. The irradiating with 351 nm light could cause the isomerization of azobenzene to the *cis* conformation, and the pores were uncapped, the cargo was released.¹¹⁸ MSNs assembled with reversible and reusable nanovalves were designed by the same research group based on the azobenzene/ α -CD recognition motif, which is capable of controlling the release of both small cargo (alizarin red S) and larger dye molecules (propidium iodide) because of azobenzene-containing stalks with different lengths.¹¹⁹ The results showed that cargo size-selectivity could be achieved by tuning the length of the azobenzene stalk.

Molecules suffering physicochemical changes under UV irradiation such as thymine possessing photodimerization-cleavage cycle¹²⁰ and photocleavable *o*-nitrobenzyl ester moiety and its derivatives¹²¹ have also been used as gatekeepers to control drug release. Besides, the structure of the PNIPAM polymers incorporating hydrophilic or hydrophobic light-sensitive monomers could transform from collapsed (insoluble) to coil (soluble) state in the presence of UV irradiation, the transformation can lead to the pores open and subsequently the loaded molecules escape from the pores.¹²²

Another strategy is grafting photoresponsive linkers such as 7-amino-coumarin derivative (CD) (at visible or NIR),¹²³ S-

coordinated Ru(bpy)₂(PPh₃)-moieties ($\lambda = 455$ nm),¹²⁴ and thioundecyl-tetraethylene-glycol-ester-*o*-nitrobenzylethyl dimethyl ammonium bromide (TUNA) (at UV region)¹²⁵ to the surface of MSNs. The photoresponsive linkers can suffer physicochemical changes or induced rupture under light irradiation, and then light-induced drug release can be obtained.

Lin and colleague¹²⁵ reported a gold nanoparticle (AuNP)-capped MSN as light sensitive DDS *via* photoresponsive linker TUNA which would give rise to the negatively charged thioundecyltetraethyleneglycolcarboxylate (TUEC) and then the capped Au NPs dissociated from the MSNs surface *via* charge repulsion upon UV irradiation. Thus, the dissociation of the Au NPs leads to the mesopores open and release of cargo molecules.

Although UV/visible light have been widely applied in light-responsive DDSs, its drawbacks limit its clinical application. The UV/visible region of the spectrum (less than 700 nm) usually has low penetration depth (~ 10 mm) due to the strong scattering properties of soft tissues, which often limited its application only on skin or external layers of organs. In addition, UV light may cause unwanted reactions including high risks for DNA damage leading to cellular apoptosis. Thus, developing longer wavelength NIR laser (in the range of 700–1000 nm) systems with lower scattering properties, deeper tissue penetration and minimal harm to tissues is required and also desirable for real clinical application.^{93,126}

The property of NIR-absorbing materials such as Au,^{127–129} CuS^{92,130} single-walled carbon nanotubes (SWNTs),¹³¹ upconverting nanoparticles (UCNPs)¹³² to convert the adsorbed photon energy through irradiation into hyperthermia, has been used to trigger the release of therapeutic molecules from NIR responsive DDSs. When combined with a thermal-responsive polymeric shell, temperature-sensitive bonds or linkers, drugs could be released under high temperature induced by NIR light irradiation. For example, DNA duplexes have been used as gatekeeper capping mesoporous silica shell and the dehybridization of the DNA duplexes led to the release of the loaded molecules.⁹¹

UCNPs have the ability to absorb lower energy NIR light photons and emit a single high energy photon of shorter wavelength in the UV or visible region owing to its expanded optical properties. He *et al.*¹³² synthesized b-phase NaYF₄:TmYb@NaYF₄ UCNPs (core: NaYF₄: 0.5 mol% Tm³⁺: 30 mol% Yb³⁺; shell = NaYF₄) coated by MSNs loaded with the anticancer drug DOX and grafted with ruthenium complexes as photoactive molecular valves. Result showed that loaded drug release could be triggered by 974 nm light with 0.35 W cm⁻² based on UCNP-assisted photochemistry. The literatures showed that the lowest intensity for UCNP-assisted photochemistry was 0.35 W cm⁻². This intensity of light is also lower than the maximum permissible exposure of skin (0.726 W cm⁻²). Such low intensity of light minimized superheating problems and avoided photo damage to biological samples. After irradiating with 0.35 W cm⁻² light (974 nm) for 5 hours, about 42% loaded DOX released, while an increased release of 78% was obtained after treating with 0.64 W cm⁻² light (974 nm) for 5 hours. The

results showed that drug release kinetics were intensity related to the power of the light irradiation.

Multiple stimuli-responsive MSNs

Compared to single stimuli-responsive drug delivery systems, dual or multi-responsive DDSs are sensitive to two or more stimuli, either in a synergistic fashion or in an independent style (Table 4), which has gained considerable attention in the current decades for its capability of further improving drug delivery.

Zhao and colleagues¹³³ capped mesoporous silica with hyaluronic acid (HA) through cleavable disulfide (SS) bonds, and the loaded DOX release occurred either in a redox responsive way by addition of glutathione (GSH) or in an enzyme responsive way by introducing of hyaluronidases (HAase). In this system, HA acted as both gatekeeper and targeting ligand owing to the specific affinity with CD44 receptors with a high level of expression on various tumor cells such as human HCT-116 cells. The MSN-SS-HA/DOX had the high drug loading efficiency up to 12.5% and *in vitro* drug release study showed that the release of DOX was triggered by GSH and HAase. Without GSH and HAase, DOX released from MSN-SS-HA/DOX was obviously inhibited with less than 20% for a period of 48 h. Nevertheless, in the presence of HAase, GSH, GSH and HAase, the cumulative amount of released DOX was significantly increased to 30%, 50% and 60% within 48 h, respectively. In addition, fluorescence-activated cell sorting (FACS) and confocal laser scanning microscopy (CLSM) showed a higher cellular uptake *via* CD44 receptor-mediated endocytosis with increasing 3.0-times and 2.7-times for 100 and 200 $\mu\text{g mL}^{-1}$ MSN-SS-HA in HCT-116 cells compared with that in CD44 receptor-negative NIH-3T3 cells. *In vitro* cytotoxicity studies showed that the IC_{50} value of MSN-SS-HA/DOX was significantly reduced to 0.6 $\mu\text{g mL}^{-1}$ in HCT-116 cells from 4.5 $\mu\text{g mL}^{-1}$ in NIH-3T3 cells. Therefore, MSN-SS-HA/DOX nanosystem could enhance the anticancer efficiency of DOX to CD44 receptor-positive cancer cells and reduce the undesirable side

effects to healthy cells/CD44 receptor-negative cells. The results suggested a potential approach *via* using a single substance to obtain dual-stimuli responsive targeted cancer therapy.

Internal-sensitivity can also be associated with external responsiveness. Very recently, Zhang *et al.*¹³⁴ reported a reduction, pH and light triple responsive nanocarriers (HMSNs-PDEAEMA) based on hollow mesoporous silica nanoparticles (HMSNs) coated by poly(2-(diethylamino)-ethyl methacrylate) (PDEAEMA). pH-Sensitive PDEAEMA polymer capped on the surface of HMSNs through linkages including reduction cleavable disulfide bond and light-cleavable *o*-nitrobenzyl ester. DOX was easily loaded into the nanocarriers with high drug loading efficiency, and the rapidly released of DOX was triggered by the stimuli of acid environment, reducing agent or UV light irradiation. In addition, the results of flow cytometry analysis, CLSM and cytotoxicity indicated that the DOX loaded HSNs-PDEAEMA was efficiently uptaken by HeLa cells, showing (i) smart control on drug delivery and release, (ii) the enhanced DOX release into the cytoplasm under external UV light irradiation, and (iii) higher cytotoxicity against HeLa cells.

Another nanosystem based on supramolecular switches showed the response to ultrasound, pH and magnetic fields. Leung and coworkers¹³⁵ reported that a nanoparticle with SPION as core, mesoporous silica as shell was functionalized with a series of metal cations complexed dibenzo-crown ether macrocycles which was utilized as gatekeeper controlling the release of cargo through ultrasound waves. In this system, pH-sensitive electrostatic interactions (such as metal chelating) or intramolecular hydrogen bonds were used to control the "ON/OFF" switching of the gatekeeper supramolecules. The dibenzo-crown ether macrocycles nanovalves could be blocked *via* chelating with Cs^+ and Na^+ ions and have the capability of loading and controlling the release of different modes of drug. In this work, the release profiles suggested that DOX released from metal cation blocked crown ether-based nanovalves capped NPs could be triggered by (i) the change in electrostatic interaction and hydrogen bonds induced by lower pH, (ii) the

Table 4 Multiple stimuli-responsive nanosystems based on mesoporous silica nanoparticles

Mechanism	Material	Release condition	Biological model	Model drug	Ref.
pH/cellulase	Cellulose	pH 4.0/cellulose	HepG2	DOX	72
Redox/enzyme	HA	GSH/hyaluronidases	HCT-116	DOX	138
pH/redox/UV	PDEAEMA/disulfide bond/ <i>o</i> -nitrobenzyl ester	pH 5.0/DTT/UV	HeLa	DOX	134
NIR/PH/thermo	Au25(SR)18/P(NIPAM-MAA)	980 nm (NIR)/tumor sites	A549, HeLa, SKOV3	DOX	139
pH/redox	Poly(allylamine hydrochloride)-citraconic anhydride/galactose-modified trimethyl chitosan-cysteine	pH 5.0/Cytoplasmic glutathione	QGY-7703	DOX/siRNA	140
Esterase/pH	Poly(β -amino ester)	Liver esterase/pH < 5.0	MDA-MB-231	DOX	141
Enzyme/redox or thermo/redox	AND logic gates (DNA)	DNase I/DTT or 50 °C/DTT	A549	Calcein	142
pH/enzyme	AND logic gate (PAA/PCL)	pH 5.5@esterase	SK-N-BE(2), HeLa, MRC-5	DOX	137
pH/redox	Disulfide bonds/benzoic-imine bond	Glutathione/pH 5.0	U87MG	DOX	143
Magnetic/NIR	Fe_3O_4 @poly-L-lysine@Au@dsDNA	Magnetic target/808 nm NIR	HeLa, nude mice	DOX	144
Ultrasound/pH/magnetic	Crown-ether/SPION	Ultrasound/pH/magnetic	L929	DOX	135

dissociation of blocked agents from dibenzo-crown ethers induced by ultrasound. Furthermore, under external magnetic field, particles could be attracted to specific lesion site *via* MF guiding and the nanoparticles showed great MRI capability, which indicated that this constructed nanosystem is potentially useful as multiple stimuli-responsive DDSs and theranostic agents.

AND logic gates could also be used to design MSNs with dual-stimuli controlled release, a MSN system with “AND” logic gate in respond to pH and light was first reported by Angelos.¹³⁶ The dual-controlled nanoparticle systems were functioned with a true “AND” logic gate in which drug release only happened in the presence of two stimuli. So the drug was released only at the required site and required time. Recently, Chen *et al.*¹³⁷ reported a MSN system with “AND” logic gate in respond to enzyme and pH based on polycaprolactone (PCL) and polyacrylic acid (PAA) functionalized MSNs (PAA-PCL-MSNs). PAA-PCL-MSNs showed the capacity of selectively controlling delivery and release of cargo in cancer cells. Esterase degradable PCL was immobilized into the pores of MSNs while pH responsive PAA was capped the outside of the MSNs to constitute a PAA-PCL-MSNs construct. With DOX as model drug, the PAA-PCL-MSNs@DOX possessed high drug loading efficiency up to 0.3 g g⁻¹, the *in vitro* drug release study showed that only in the coexistence of low pH and esterase, DOX release could occur. The IC₅₀ of the PAA-PCL-MSNs@DOX in normal fibroblasts MRC-5 was 8-times than that in neuroblastoma SK-N-BE(2) cell.

This 8-fold divergence demonstrated that PAA-PCL-MSNs@DOX possessed the higher cytotoxicity to cancer cells than normal cells. The release based on “AND” logic gate could reach smart control in complicated physiological environment, then decreasing undesirable toxic side effects on normal cells and enhancing therapeutic efficacy of target cells.

Active targeting MSNs

Active targeting as a complementary strategy to EPR effect has opened up a new area for traditional chemotherapy to enhance the efficiency of anti-cancer, which known as ligand-mediated targeting involving functionalization of the MSNs surface with active targeting ligands. The active targeting ligands, such as small molecules, peptides, antibodies, proteins, saccharides and aptamers, have specific affinity to the over-expressed receptors on the tumor cells. Typically, there are three paths (targeting to tumor vessels, tumor cells, nuclear) to achieve effective enrichment of drugs in tumor tissues (Fig. 4). The most relevant results derived from the conjugation of active targeting ligands to MSNs-based nanosystems to promote specific recognition and cellular uptake by cancer cells are summarized in Table 5.

Vessel targeting MSNs

Different from normal tissues, many proteins show specific over-expression on the surface of tumor-associated endothelial




Fig. 4 Schematic illustration of active targeted drug delivery based on MSNs for effective cancer therapy: (1) tumor vascular targeting. (2) Tumor cell targeting (3) nuclear targeting.

Table 5 Active targeting ligands conjugated to mesoporous silica nanoparticles-based nanosystems that permit their specific recognition^a

Site	Targeting ligand	Targets/mechanism	Model	Model drug	Stimuli-responsive	Ref.
Tumor cell membrane	HA	CD44 receptor	MDA-MB-231	Rhodamine B		69
	HA	CD44 receptor	HCT-116	DOX		145
	MSN-SS-HA	CD44 receptor	HCT-116	DOX	Redox and enzyme redox and enzyme control release, improved cytotoxicity and cellular uptake	133
	CMS-SS-oHA	CD44 receptor	HCT-116	6-MP	Redox improved cytotoxicity and cellular uptake	63
	FA	Folate receptor	A549, HeLa	DOX		146
	DOX@HPSN-Salphdc-FA	Folate receptor	HepG2	DOX	PH, minimal toxic side effect, induce cell apoptosis, inhibition of tumor growth	147
	MSN-FA@gelatin-PEG	Folate receptor	HT-29	DOX	Enzyme, MMP-2 induced release, target endocytosis	71
	SBA-PEG-FA	Folate receptor	HepG2	DOX	PH, enhanced cancer cell killing efficacy	21
	FA-PEI-HMSN@Dox@siRNA	Folate receptor	HeLa	DOX and siRNA	PH, enhanced therapeutic efficacy co-delivery of DOX and siRNA	148
	MSNs-S-S-HP-LA	Galactose receptor	HepG2	DOX	Redox induce cell apoptosis, inhibition of tumor growth	55
	HMSNs-S-S-Ada/ β -CD-LA	Asialoglycoprotein receptor	HepG2	DOX	Redox, inhibited tumor growth with the minimized side effect	58
	anti-EpCAMDNA aptamer (Ap)	EpCAM	SW620	DOX		149
	YY146 (an anti-CD146 antibody)	CD146	U87MG	DOX		150
	Antibody/single-chain variable fragment (Ab/scFv)	Specific affinity receptor	OVCAR-5	Bevacizumab		151
	K4YRGD peptide	α v β 3 receptor	HepG2	DOX		152
	Lactose	ASGPR	HepG2 SMMC7721	Docetaxel		153
	AS1411 aptamer	Nucleolin	HeLa	DTX		154
	AS1411 aptamer ATP aptamer	Nucleolin	HeLa	DOX	ATP ATP-triggered release, high therapeutic efficacy	155
	PTX-MSNs@AgNPs-PEG/sgc8 (aptamer)	—	CEM	Paclitaxel (PTX)	Redox, inhibition of tumor growth	156
Tf- Ag@SiO ₂ @mSiO ₂ @CS-PMAA	Transferrin receptor (TfR)	HeLa	DOX	pH-responsive, SERS-traceable, cancer cells target	157	
N3GPLGRGRGDK-Ad	α v β 3 integrins	SCC-7	DOX		158	
PEI-cRGD	α v β 3 integrins	Blood-brain barrier model	DOX		159	
cRGDfK	α v β 3 integrins	MDA-MB-231 triple-negative breast cancer	Arsenic trioxide (ATO)		160	
CRGDKGPDC	α 2 β 3 receptor	HeLa	Combretastatin A4, DOX		161	
CRGDyK	α v β 3 integrins	U87MG	Sunitinib (SUN)		162	
K ₈ (RGD) ₂	α v β 3 integrins	U87MG	DOX		163	

Table 5 (Contd.)

Site	Targeting ligand	Targets/mechanism	Model	Model drug	Stimuli-responsive	Ref.
	MSN-GFLGR7RGDS/ α -CD	α v β 3 integrins	HeLa	DOX	Enzyme superior tumor targeting, drug internalization, cytotoxicity, and <i>in vivo</i> antitumor efficacy	65
	cRGD	α v β 3 integrins	SCC-7	CPT	Tumor tissues (vasculature)	164
	MSN-SS-RGDFFFFC-MPEG	α v β 3 integrins	U-87 MG	DOX	Redox, PH selectively tumor cell killing	143
	HB5 aptamer	HER2	SK-BR-3	DOX		165
	PEGA-pVEC peptide	—	MCF-7	(-)-Epigallocatechin-3-gallate		166
	Vascular endothelial growth factor (VEGF)	VEGF receptor	SKOV3	siRNA		167
	VEGF121	VEGF receptor	U87MG	Sunitinib (SUN)		168
	Anti-TRC105	CD105	HUVE-Cs	DOX		169
	anti-VCAM-1	VCAM-1 receptors	HUVEC-CS	Fluorescein isothiocyanate (FITC)		170
Nuclei	TAT peptide	Nuclear membrane receptors	MCF-7/ADR	DOX		171
	MONs-PTAT	Nuclear membrane receptors	HeLa	DNA		172
	MSN ^{SA} -TAT& ^{DMA} K ₁₁	Stepwise-acid-active	HeLa	DOX		173
	QDs@mSiO ₂ -CPP (TAT, PGFK, oligoanionic-inhibitory domain)	Cathepsin B protease	A549	DOX	Enzyme selectively release drug into the nucleus of targeted tumor cells with high tumor cytotoxicity and minimum side effects	67
	Dexamethasone (DEX)	Glucocorticoid receptor (GR)	HeLa	DOX		174
Multistage target						
Tumor and nuclei	FA and dexamethasone (DEX)	Folate receptor and glucocorticoid receptor (GR)	HeLa	DOX		174
Tumor cells and vessels	tLyp-1 peptide	Neuropilin (NRP)	MDA-MB-231, HUVECs	DOX		175
Vascular-cell nuclear	RGD peptides, TAT peptide	α v β 3 integrins Nuclear membrane receptors	HeLa	DOX		176
Tissue-cell-nuclear	Magnetic, FA, TAT peptide	Magnetic target, folate receptor, nuclear-target	HeLa	Camptothecin (CPT)		177

^a anti-EpCAMDNA Ap: (5'-amino-CAC TAC AGA GGT TGC GTC TGT CCCACG TTG TCA TGG GGG GTTGGC CTG-3', MW = 748.70), HB5Ap: (5'-AACCGCCCAAATCCCTAA-GAGTCTGCACTTGTTCATTTGTATATGTATTTGGTTTGGCTCTCACA-GACACACTACACACGCACA-3', 86 bp), tLyp-1: (sequence CGNKRTR) PEGA-pVEC peptides (cCPGPEGAGC-LLILRRIRKQAHASK-NH₂), LA: lactobionic acid, ASGPR: asialoglycoprotein receptor, EpCAM: epithelial cell adhesion molecule, HER2: human epithelial growth factor receptor 2, 6-MP: 6-mercaptopurine, HA: hyaluronic acid, SERS: surface enhanced Raman scattering.

cells due to the abnormal overgrowth of intratumoral vasculature, which can be utilized as targets for targeted drug delivery and cancer treatment. According to the literatures, targeting to the endothelial cells of the tumor vessels and subsequently killing them can lead to the necrosis of tumors because tumor vasculatures are the transport channel of nutrition which guarantees the fast proliferation of tumor cells,¹⁷⁸ which has become a promising alternative in treating solid tumors. In 2013, Chen *et al.*¹⁶⁹ reported the first example of *in vivo* tumor

vascular targeted drug delivery system based on MSNs. In this nanosystem, TRC105 antibody targeting to CD105 receptor was conjugated onto MSNs surface. In the 4T1 tumor tissue, the receptors (CD105) only overexpressed in the tumor vasculature but did not express on 4T1 tumor cell. Active vessel targeting giving rise to ~2 times enhancement of tumor uptake comparing to passive targeting only based on the EPR effect.

Since then, various tumor vascular targeting ligands, such as vascular endothelial growth factor (VEGF) specific for VEGF

receptors (VEGFRs), arginine-glycine-aspartic acid (RGD) peptides targeting to $\alpha\text{v}\beta\text{3}$ integrin receptor, HB5 aptamer which was specific for human epithelial growth factor receptor 2 (HER2), anti-VCAM-1 monoclonal antibody specific for vascular cell adhesion molecule-1 (VCAM-1) receptors, have been connected to the surface of MSNs to develop vascular targeted drug delivery systems with enhanced therapeutic efficiency.

Very recently, Li *et al.*¹⁶¹ reported a novel vascular-targeting co-delivery DDS based on targeting molecules (iRGD peptide) modified MSNs. In this system, antiangiogenic agent (combretastatin A4) and chemotherapeutic drug (DOX) were payloaded, leading to significantly improved anti-cancer efficacy even at a very low DOX dose (1.5 mg kg^{-1}). Furthermore, the disruption of vascular structure caused by combretastatin A4 which was released quickly at tumor vasculatures had a synergistic effect with DOX which released slowly in the subsequent delivery of DOX into tumors.

Tumor cell targeting MSNs

After reaching tumor tissues, drug loaded nanocarriers are often expected to target to tumor cells through specific interaction between ligand and receptor, leading to the enhanced cellular uptake and drug delivery efficiency and the enhanced therapeutic efficacy. Ligand-mediated targeting to tumor cells need meet the following requirements: (I) a threefold over-expression of the targeted receptor on the cancer cell compared with normal cells is generally considered to be sufficient to warrant further investigation, although greater upregulation is preferred.¹⁷⁹ (II) The density of active targeting ligands on the surface of nanoparticles should be carefully manipulated and optimized in order to obtain maximized targeting and therapy efficiency. Because the ligand/nanoparticle ratio strongly affects the cell recognition specificity, so greater selectivity and targeting efficiency can be obtained with higher density of active targeting ligands.¹⁸⁰ But excessively high density of active targeting ligands may increase the steric hindrance effect and lead to poor cellular uptake efficiency.¹⁸¹ (III) Preventing targeting ligands coated by the plasma protein is also a noteworthy issue because the targeting ligands can be shielded by opsonization, which can result in loss of their targeting ability in a complex *in vivo* environment.¹⁸² (IV) The targeted receptor on the cancer cell can induce endocytosis.

Various tumor cell targeting ligands such as antibodies (anti-CD146 antibody, antibody fragment (Ab-scFv)), proteins (transferrin (Tf)), peptides (K4YRGD peptide), saccharides (hyaluronic acid (HA)), lactobionic acid (LA), lactose, small molecules (folic acid (FA)), aptamers (anti-EpCAMDNA aptamer, AS1411 aptamer), have been conjugated onto MSNs surface to receive tumor cell targeted property.

Quan *et al.*¹⁵³ designed a hepatoma targeting DDS based on lactose conjugated MSNs (Lac-MSNs) with anticancer drug DTX loaded. The DTX-Lac-MSNs showed specific targeting to ASGPR-positive SMMC7721 and HepG2 cells, and the cellular uptake of Lac-MSNs was an energy-consuming process and predominated by clathrin-mediated endocytosis. Thanks to active targeting, significantly enhanced

inhibition of the growth of HepG2 and SMMC7721 cells *in vitro* was obtained.

Nuclear-targeting MSNs

The nucleus is important space for the storage, replication and transcription of genetic material and plays an important role in cell metabolism, growth and differentiation. Therapeutic genes must enter the cell nucleus and correct dysfunctional and/or missing genes. Some anti-cancer drugs, such as cisplatin and DOX, must enter into the cell nucleus to induce apoptosis. Therefore, the nuclei of cancer cells has become an ultimate target point and nuclear-targeted treatment systems are hoped to be more efficiently and directly deliver therapeutic drugs to kill tumor cells. There are a lot of nuclear pore complexes distributing on the nuclear membrane, the pore with a diameter value of 20–70 nm. The diameter of the pore is related to the cell type and cell cycle, especially, the nuclear pore diameter of tumor cells is bigger than normal cells.¹⁸³ The classical cytoplasm-to-nuclear transport of nanocarriers must pass through the nuclear pore, nanocarriers with the aid of proteins which contain nuclear localization sequences (NLS) form complexes with importin α/β , then interact with nucleoporins within the NPCs, and finally transversely enter the nuclei from cytoplasm.¹⁸³ Therefore, enough small nanocarriers or dilated nuclear pore and conjugated appropriate nuclear targeting ligands (such as cell-penetrating peptides (CPPs) which contain nuclear localization sequences (NLS)), are two critical presuppositions for the nuclear-targeted nanocarriers. Besides these, the nanocarriers should be tumor specific without any harmful side effects and have the ability to escape from endo/lysosomal to avoid the internalized nanocarriers and cargos being degraded.

Lin *et al.*¹⁷⁴ reported a cancer-cell-specific nuclear targeted delivery system based on both FA and dexamethasone (DEX) targeting ligand modified MSNs. In which, the nuclear targeting ligand dexamethasone is a potent glucocorticoid with the capability of enlarging nuclear pore up to 60 nm during the translocation process, it can promote transport from cytoplasm to nucleus *via* specifically binding to the nuclear receptor, glucocorticoid receptor (GR) expressed in almost style cell. FA acting as tumor cell targeting ligand can enhance cancer cellular uptake. The results demonstrated that the constructed FA-MSN-DEX showed higher anticancer efficacy of DOX on HeLa cells *via* enhanced cellular uptake and active nucleus accumulation with the calculated IC_{50} of $0.78 \mu\text{g mL}^{-1}$ at 48 h.

Conclusions

In the war against cancer, conventional chemotherapy is still the main approach among various types of cancer treatments. While conventional chemotherapy will cause severe harmful side-effects due to nonspecific uptake by healthy cells and high-doses administration of therapeutic agents. The nonspecific cellular uptake of the drug by healthy cells is an important obstacle during the treatment of cancer. Therefore, it is important to target delivery of anticancer drugs with suitable

nanocarriers. MSNs are promising candidates in target delivery of anticancer drugs for its unique physical–chemical properties. Through conjugating of various functional groups on MSNs, stimuli-responsive and active targeted anticancer drug delivery systems have been successfully prepared. The wide range of endogenous stimuli (e.g. pH, redox, enzymes, temperature) or exogenous stimuli (e.g. light, magnetic, ultrasound) is able to trigger the release of anticancer drug at the right place and time. And various functional groups or molecules can be combined with MSNs, which allows more flexibility in design of stimuli-responsive DDSs. Yet, the design of sensitive nanocarriers to endogenous or exogenous stimuli may exist severe limitation in practice, because the difference of internal stimuli is not enough big and external stimuli is difficult to accurately locate. To improve practicability, multiple stimuli-responsive drug delivery systems or/and combination with active targeting have been designed to cover the insufficiency of single stimuli-sensitive nanosystems, thereby achieve more accurately controlled release of drug. As for active target, nanocarriers based on MSNs possessing higher targeting efficiency and treatment efficiency are needed, the role and contribution of tumor cell targeting ligands to tumor site specific accumulation at *in vivo* conditions need more detailed studies.

Although a number of stimuli-responsive and active targeting nanosystems have been reported *in vitro* proofs of concept, only a few have been performed *in vivo* preclinical research, and none has reached the clinical stage. In addition, researches about the toxicity and benefit-to-risk ratio after long-term use, the feature of pharmacokinetic *in vivo* are severe insufficient. Therefore, to develop a biodegradable, non-toxic, safety, high targeting efficiency drug delivery system based on MSNs is an important direction and main objective in the future.

Acknowledgements

This work was supported by the Natural Science Foundation of Shandong Province, China (No. ZR2015HM032).

References

- 1 S. Nazir, T. Hussain, A. Ayub, U. Rashid and A. J. MacRobert, *Nanomedicine*, 2014, **10**, 19–34.
- 2 W. X. Mai and H. Meng, *Integr. Biol.*, 2013, **5**, 19–28.
- 3 Y. Yang and C. Yu, *Nanomedicine: Nanotechnology, Biology and Medicine*, 2015, **12**, 317–332.
- 4 D. Douroumis, I. Onyesom, M. Maniruzzaman and J. Mitchell, *Crit. Rev. Biotechnol.*, 2013, **33**, 229–245.
- 5 J. L. Vivero-Escoto, I. I. Slowing, B. G. Trewyn and V. S. Lin, *Small*, 2010, **6**, 1952–1967.
- 6 J. Lu, M. Liong, J. I. Zink and F. Tamanoi, *Small*, 2007, **3**, 1341–1346.
- 7 L. Sun, Y. Wang, T. Jiang, X. Zheng, J. Zhang, J. Sun, C. Sun and S. Wang, *ACS Appl. Mater. Interfaces*, 2013, **5**, 103–113.
- 8 P. Nadrah, F. Porta, O. Planinsek, A. Kros and M. Gaberscek, *PCCP Phys. Chem. Chem. Phys.*, 2013, **15**, 10740–10748.
- 9 Y. Zhao, J. L. Vivero-Escoto, I. I. Slowing, B. G. Trewyn and V. S. Lin, *Expert Opin. Drug Delivery*, 2010, **7**, 1013–1029.
- 10 S. P. Hudson, R. F. Padera, R. Langer and D. S. Kohane, *Biomaterials*, 2008, **29**, 4045–4055.
- 11 M. Colilla, B. González and M. Vallet-Regí, *Biomater. Sci.*, 2013, **1**, 114–134.
- 12 J. Lu, M. Liong, Z. Li, J. I. Zink and F. Tamanoi, *Small*, 2010, **6**, 1794–1805.
- 13 Y. Wang, Q. Zhao, N. Han, L. Bai, J. Li, J. Liu, E. Che, L. Hu, Q. Zhang, T. Jiang and S. Wang, *Nanomedicine*, 2015, **11**, 313–327.
- 14 C. Kresge, M. Leonowicz, W. Roth, J. Vartuli and J. Beck, *Nature*, 1992, **359**, 710–712.
- 15 M. Vallet-Regí, A. Ramila, R. Del Real and J. Pérez-Pariente, *Chem. Mater.*, 2001, **13**, 308–311.
- 16 Y. Chen, H. Chen and J. Shi, *Expert Opin. Drug Delivery*, 2014, **11**, 917–930.
- 17 F. Danhier, O. Feron and V. Preat, *J. Controlled Release*, 2010, **148**, 135–146.
- 18 R. Liu, Y. Zhang, X. Zhao, A. Agarwal, L. J. Mueller and P. Feng, *J. Am. Chem. Soc.*, 2010, **132**, 1500–1501.
- 19 Y. Chen, K. Ai, J. Liu, G. Sun, Q. Yin and L. Lu, *Biomaterials*, 2015, **60**, 111–120.
- 20 Q. Gan, X. Lu, Y. Yuan, J. Qian, H. Zhou, X. Lu, J. Shi and C. Liu, *Biomaterials*, 2011, **32**, 1932–1942.
- 21 K. Yang, H. Luo, M. Zeng, Y. Jiang, J. Li and X. Fu, *ACS Appl. Mater. Interfaces*, 2015, **7**, 17399–17407.
- 22 C. H. Lee, S. H. Cheng, I. Huang, J. S. Souris, C. S. Yang, C. Y. Mou and L. W. Lo, *Angew. Chem.*, 2010, **122**, 8390–8395.
- 23 M. Chen, X. He, K. Wang, D. He, S. Yang, P. Qiu and S. Chen, *J. Mater. Chem. B*, 2014, **2**, 428–436.
- 24 L. Chen, J. Di, C. Cao, Y. Zhao, Y. Ma, J. Luo, Y. Wen, W. Song, Y. Song and L. Jiang, *Chem. Commun.*, 2011, **47**, 2850–2852.
- 25 Z. Zou, D. He, X. He, K. Wang, X. Yang, Z. Qing and Q. Zhou, *Langmuir*, 2013, **29**, 12804–12810.
- 26 X. Hu, Y. Wang and B. Peng, *Chem.-Asian J.*, 2014, **9**, 319–327.
- 27 S. Niedermayer, V. Weiss, A. Herrmann, A. Schmidt, S. Datz, K. Muller, E. Wagner, T. Bein and C. Brauchle, *Nanoscale*, 2015, **7**, 7953–7964.
- 28 J. Zheng, X. Tian, Y. Sun, D. Lu and W. Yang, *Int. J. Pharm.*, 2013, **450**, 296–303.
- 29 W. Feng, X. Zhou, C. He, K. Qiu, W. Nie, L. Chen, H. Wang, X. Mo and Y. Zhang, *J. Mater. Chem. B*, 2013, **1**, 5886–5898.
- 30 W. Feng, W. Nie, C. He, X. Zhou, L. Chen, K. Qiu, W. Wang and Z. Yin, *ACS Appl. Mater. Interfaces*, 2014, **6**, 8447–8460.
- 31 J. Wang, H. Liu, F. Leng, L. Zheng, J. Yang, W. Wang and C. Z. Huang, *Microporous Mesoporous Mater.*, 2014, **186**, 187–193.
- 32 P. Zhang, T. Wu and J. L. Kong, *ACS Appl. Mater. Interfaces*, 2014, **6**, 17446–17453.
- 33 X. Xu, S. Lü, C. Gao, X. Wang, X. Bai, N. Gao and M. Liu, *Chem. Eng. J.*, 2015, **266**, 171–178.
- 34 J.-T. Sun, C.-Y. Hong and C.-Y. Pan, *J. Phys. Chem. C*, 2010, **114**, 12481–12486.
- 35 L. Yuan, Q. Tang, D. Yang, J. Z. Zhang, F. Zhang and J. Hu, *J. Phys. Chem. C*, 2011, **115**, 9926–9932.

- 36 T. Chen, W. Wu, H. Xiao, Y. Chen, M. Chen and J. Li, *ACS Macro Lett.*, 2016, **5**, 55–58.
- 37 C. Chen, F. Pu, Z. Huang, Z. Liu, J. Ren and X. Qu, *Nucleic Acids Res.*, 2011, **39**, 1638–1644.
- 38 H. Meng, M. Xue, T. Xia, Y.-L. Zhao, F. Tamanoi, J. F. Stoddart, J. I. Zink and A. E. Nel, *J. Am. Chem. Soc.*, 2010, **132**, 12690–12697.
- 39 Y.-L. Zhao, Z. Li, S. Kabehie, Y. Y. Botros, J. F. Stoddart and J. I. Zink, *J. Am. Chem. Soc.*, 2010, **132**, 13016–13025.
- 40 L. Du, H. Song and S. Liao, *Microporous Mesoporous Mater.*, 2012, **147**, 200–204.
- 41 S. Angelos, N. M. Khashab, Y.-W. Yang, A. Trabolshi, H. A. Khatib, J. F. Stoddart and J. I. Zink, *J. Am. Chem. Soc.*, 2009, **131**, 12912–12914.
- 42 J. Zhang, D. Wu, M.-F. Li and J. Feng, *ACS Appl. Mater. Interfaces*, 2015, **7**, 26666–26673.
- 43 H. P. Rim, K. H. Min, H. J. Lee, S. Y. Jeong and S. C. Lee, *Angew. Chem., Int. Ed.*, 2011, **50**, 8853–8857.
- 44 Q. Zheng, Y. Hao, P. Ye, L. Guo, H. Wu, Q. Guo, J. Jiang, F. Fu and G. Chen, *J. Mater. Chem. B*, 2013, **1**, 1644–1648.
- 45 Z. Li, J. C. Barnes, A. Bosoy, J. F. Stoddart and J. I. Zink, *Chem. Soc. Rev.*, 2012, **41**, 2590–2605.
- 46 L. Bai, Q. Zhao, J. Wang, Y. Gao, Z. Sha, D. Di, N. Han, Y. Wang, J. Zhang and S. Wang, *Nanotechnology*, 2015, **26**, 165704.
- 47 D. Shao, X. Zhang, W. Liu, F. Zhang, X. Zheng, P. Qiao, J. Li, W. F. Dong and L. Chen, *ACS Appl. Mater. Interfaces*, 2016, **8**, 4303–4308.
- 48 G. Saito, J. A. Swanson and K.-D. Lee, *Adv. Drug Delivery Rev.*, 2003, **55**, 199–215.
- 49 K. T. Nguyen and Y. Zhao, *Acc. Chem. Res.*, 2015, **48**, 3016–3025.
- 50 C.-Y. Lai, B. G. Trewyn, D. M. Jeftinija, K. Jeftinija, S. Xu, S. Jeftinija and V. S.-Y. Lin, *J. Am. Chem. Soc.*, 2003, **125**, 4451–4459.
- 51 F. Torney, B. G. Trewyn, V. S. Lin and K. Wang, *Nat. Nanotechnol.*, 2007, **2**, 295–300.
- 52 S. Giri, B. G. Trewyn, M. P. Stellmaker and V. S. Y. Lin, *Angew. Chem.*, 2005, **117**, 5166–5172.
- 53 Q. Zhao, C. Wang, Y. Liu, J. Wang, Y. Gao, X. Zhang, T. Jiang and S. Wang, *Int. J. Pharm.*, 2014, **477**, 613–622.
- 54 L. Chen, Z. Zheng, J. Wang and X. Wang, *Microporous Mesoporous Mater.*, 2014, **185**, 7–15.
- 55 L. Dai, J. Li, B. Zhang, J. Liu, Z. Luo and K. Cai, *Langmuir*, 2014, **30**, 7867–7877.
- 56 L. Sun, Y.-J. Liu, Z.-Z. Yang and X.-R. Qi, *RSC Adv.*, 2015, **5**, 55566–55578.
- 57 J. Lee, H. Kim, S. Han, E. Hong, K.-H. Lee and C. Kim, *J. Am. Chem. Soc.*, 2014, **136**, 12880–12883.
- 58 Z. Luo, Y. Hu, K. Cai, X. Ding, Q. Zhang, M. Li, X. Ma, B. Zhang, Y. Zeng and P. Li, *Biomaterials*, 2014, **35**, 7951–7962.
- 59 Q. Zhang, X. Wang, P. Z. Li, N. K. Truc, X. J. Wang, Z. Luo, H. Zhang, N. S. Tan and Y. Zhao, *Adv. Funct. Mater.*, 2014, **24**, 2413.
- 60 B. Zhang, Z. Luo, J. Liu, X. Ding, J. Li and K. Cai, *J. Controlled Release*, 2014, **192**, 192–201.
- 61 H. He, H. Kuang, L. Yan, F. Meng, Z. Xie, X. Jing and Y. Huang, *PCCP Phys. Chem. Chem. Phys.*, 2013, **15**, 14210–14218.
- 62 L. Palanikumar, E. S. Choi, J. Y. Cheon, S. H. Joo and J. H. Ryu, *Adv. Funct. Mater.*, 2014, **25**, 957–965.
- 63 Q. Zhao, H. Geng, Y. Wang, Y. Gao, J. Huang, Y. Wang, J. Zhang and S. Wang, *ACS Appl. Mater. Interfaces*, 2014, **6**, 20290–20299.
- 64 X. Yang, D. He, X. He, K. Wang, Z. Zou, X. Li, H. Shi, J. Luo and X. Yang, *Part. Part. Syst. Character.*, 2015, **32**, 205–212.
- 65 Y. J. Cheng, G. F. Luo, J. Y. Zhu, X. D. Xu, X. Zeng, D. B. Cheng, Y. M. Li, Y. Wu, X. Z. Zhang, R. X. Zhuo and F. He, *ACS Appl. Mater. Interfaces*, 2015, **7**, 9078–9087.
- 66 C. de la Torre, L. Mondragon, C. Coll, F. Sancenon, M. D. Marcos, R. Martinez-Manez, P. Amoros, E. Perez-Paya and M. Orzaez, *Chemistry*, 2014, **20**, 15309–15314.
- 67 J. Li, F. Liu, Q. Shao, Y. Min, M. Costa, E. K. Yeow and B. Xing, *Adv. Healthcare Mater.*, 2014, **3**, 1230–1239.
- 68 G. Zhang, M. Yang, D. Cai, K. Zheng, X. Zhang, L. Wu and Z. Wu, *ACS Appl. Mater. Interfaces*, 2014, **6**, 8042–8047.
- 69 Z. Chen, Z. Li, Y. Lin, M. Yin, J. Ren and X. Qu, *Chem.-Eur. J.*, 2013, **19**, 1778–1783.
- 70 J.-H. Xu, F.-P. Gao, L.-L. Li, H. L. Ma, Y.-S. Fan, W. Liu, S.-S. Guo, X.-Z. Zhao and H. Wang, *Microporous Mesoporous Mater.*, 2013, **182**, 165–172.
- 71 Z. Zou, X. He, D. He, K. Wang, Z. Qing, X. Yang, L. Wen, J. Xiong, L. Li and L. Cai, *Biomaterials*, 2015, **58**, 35–45.
- 72 A. Hakeem, F. Zahid, R. Duan, M. Asif, T. Zhang, Z. Zhang, Y. Cheng, X. Lou and F. Xia, *Nanoscale*, 2016, **8**, 5089–5097.
- 73 A. Agostini, L. Mondragon, A. Bernardos, R. Martinez-Manez, M. D. Marcos, F. Sancenon, J. Soto, A. Costero, C. Manguan-Garcia, R. Perona, M. Moreno-Torres, R. Aparicio-Sanchis and J. R. Murguia, *Angew. Chem., Int. Ed. Engl.*, 2012, **51**, 10556–10560.
- 74 L. A. Shuman Moss, S. Jensen-Taubman and W. G. Stetler-Stevenson, *Am. J. Pathol.*, 2012, **181**, 1895–1899.
- 75 Z. Zhou, S. Zhu and D. Zhang, *J. Mater. Chem.*, 2007, **17**, 2428.
- 76 A. Zintchenko, M. Ogris and E. Wagner, *Bioconjugate Chem.*, 2006, **17**, 766–772.
- 77 M. Keerl, V. Smirnovas, R. Winter and W. Richtering, *Macromolecules*, 2008, **41**, 6830–6836.
- 78 T. Hoare, J. Santamaria, G. F. Goya, S. Irusta, D. Lin, S. Lau, R. Padera, R. Langer and D. S. Kohane, *Nano Lett.*, 2009, **9**, 3651–3657.
- 79 M. Karesoja, J. Mckee, E. Karjalainen, S. Hietala, L. Bergman, M. Linden and H. Tenhu, *J. Polym. Sci., Part A: Polym. Chem.*, 2013, **51**, 5012–5020.
- 80 J. T. Sun, Z. Q. Yu, C. Y. Hong and C. Y. Pan, *Macromol. Rapid Commun.*, 2012, **33**, 811–818.
- 81 E. Aznar, L. Mondragon, J. V. Ros-Lis, F. Sancenon, M. D. Marcos, R. Martinez-Manez, J. Soto, E. Perez-Paya and P. Amoros, *Angew. Chem., Int. Ed. Engl.*, 2011, **50**, 11172–11175.
- 82 H. Yan, C. Teh, S. Sreejith, L. Zhu, A. Kwok, W. Fang, X. Ma, K. T. Nguyen, V. Korzh and Y. Zhao, *Angew. Chem., Int. Ed. Engl.*, 2012, **51**, 8373–8377.

- 83 X. Wu, Z. Wang, D. Zhu, S. Zong, L. Yang, Y. Zhong and Y. Cui, *ACS Appl. Mater. Interfaces*, 2013, **5**, 10895–10903.
- 84 A. Schlossbauer, S. Warncke, P. M. Gramlich, J. Kecht, A. Manetto, T. Carell and T. Bein, *Angew. Chem., Int. Ed. Engl.*, 2010, **49**, 4734–4737.
- 85 Z. Yu, N. Li, P. Zheng, W. Pan and B. Tang, *Chem. Commun.*, 2014, **50**, 3494–3497.
- 86 G. Martelli, H. R. Zope, M. B. Capell and A. Kros, *Chem. Commun.*, 2013, **49**, 9932–9934.
- 87 C. de la Torre, A. Agostini, L. Mondragon, M. Orzaez, F. Sancenon, R. Martinez-Manez, M. D. Marcos, P. Amoros and E. Perez-Paya, *Chem. Commun.*, 2014, **50**, 3184–3186.
- 88 C. Liu, J. Guo, W. Yang, J. Hu, C. Wang and S. Fu, *J. Mater. Chem.*, 2009, **19**, 4764–4770.
- 89 A. Baeza, E. Guisasola, E. Ruiz-Hernández and M. Vallet-Regí, *Chem. Mater.*, 2012, **24**, 517–524.
- 90 C. R. Thomas, D. P. Ferris, J.-H. Lee, E. Choi, M. H. Cho, E. S. Kim, J. F. Stoddart, J.-S. Shin, J. Cheon and J. I. Zink, *J. Am. Chem. Soc.*, 2010, **132**, 10623–10625.
- 91 Y. T. Chang, P. Y. Liao, H. S. Sheu, Y. J. Tseng, F. Y. Cheng and C. S. Yeh, *Adv. Mater.*, 2012, **24**, 3309–3314.
- 92 Y. Zhang, Z. Hou, Y. Ge, K. Deng, B. Liu, X. Li, Q. Li, Z. Cheng, P. Ma, C. Li and J. Lin, *ACS Appl. Mater. Interfaces*, 2015, **7**, 20696–20706.
- 93 S. Mura, J. Nicolas and P. Couvreur, *Nat. Mater.*, 2013, **12**, 991–1003.
- 94 S. Laurent, S. Dutz, U. O. Hafeli and M. Mahmoudi, *Adv. Colloid Interface Sci.*, 2011, **166**, 8–23.
- 95 B. Ruhle, S. Datz, C. Argyo, T. Bein and J. I. Zink, *Chem. Commun.*, 2016, **52**, 1843–1846.
- 96 P. Saint-Cricq, S. Deshayes, J. I. Zink and A. M. Kasko, *Nanoscale*, 2015, **7**, 13168–13172.
- 97 F. Liu, J. Wang, Q. Cao, H. Deng, G. Shao, D. Y. Deng and W. Zhou, *Chem. Commun.*, 2015, **51**, 2357–2360.
- 98 E. Guisasola, A. Baeza, M. Talelli, D. Arcos, M. Moros, J. M. de la Fuente and M. Vallet-Regí, *Langmuir*, 2015, **31**, 12777–12782.
- 99 Y. Wang and H. Gu, *Adv. Mater.*, 2015, **27**, 576–585.
- 100 H. Wu, G. Liu, S. Zhang, J. Shi, L. Zhang, Y. Chen, F. Chen and H. Chen, *J. Mater. Chem.*, 2011, **21**, 3037.
- 101 C. Tao and Y. Zhu, *Dalton Trans.*, 2014, **43**, 15482–15490.
- 102 P.-J. Chen, S.-H. Hu, C.-S. Hsiao, Y.-Y. Chen, D.-M. Liu and S.-Y. Chen, *J. Mater. Chem.*, 2011, **21**, 2535.
- 103 E. Ruiz-Hernandez, A. Baeza and M. Vallet-Regí, *ACS Nano*, 2011, **5**, 1259–1266.
- 104 E. Bringas, O. Koyuren, D. V. Quach, M. Mahmoudi, E. Aznar, J. D. Roehling, M. D. Marcos, R. Martinez-Manez and P. Stroeve, *Chem. Commun.*, 2012, **48**, 5647–5649.
- 105 C. R. Thomas, D. P. Ferris, J. H. Lee, E. Choi, M. H. Cho, E. S. Kim, J. F. Stoddart, J. S. Shin, J. Cheon and J. I. Zink, *J. Am. Chem. Soc.*, 2010, **132**, 10623–10625.
- 106 B. Sahoo, K. S. Devi, S. Dutta, T. K. Maiti, P. Pramanik and D. Dhara, *J. Colloid Interface Sci.*, 2014, **431**, 31–41.
- 107 D. Yang, K. Wei, Q. Liu, Y. Yang, X. Guo, H. Rong, M. L. Cheng and G. Wang, *Mater. Sci. Eng., C*, 2013, **33**, 2879–2884.
- 108 N. Rapoport, K. H. Nam, R. Gupta, Z. Gao, P. Mohan, A. Payne, N. Todd, X. Liu, T. Kim, J. Shea, C. Scaife, D. L. Parker, E. K. Jeong and A. M. Kennedy, *J. Controlled Release*, 2011, **153**, 4–15.
- 109 A. K. Wood and C. M. Sehgal, *Ultrasound Med. Biol.*, 2015, **41**, 905–928.
- 110 S. R. Sirsi and M. A. Borden, *Adv. Drug Delivery Rev.*, 2014, **72**, 3–14.
- 111 X. Wang, H. Chen, Y. Zheng, M. Ma, Y. Chen, K. Zhang, D. Zeng and J. Shi, *Biomaterials*, 2013, **34**, 2057–2068.
- 112 P. Cintas, S. Tagliapietra, M. Caporaso, S. Tabasso and G. Cravotto, *Ultrason. Sonochem.*, 2015, **25**, 8–16.
- 113 J. Wang, M. Pelletier, H. Zhang, H. Xia and Y. Zhao, *Langmuir*, 2009, **25**, 13201–13205.
- 114 J. N. Brantley, K. M. Wiggins and C. W. Bielawski, *Science*, 2011, **333**, 1606–1609.
- 115 J. Xuan, O. Boissière, Y. Zhao, B. Yan, L. Tremblay, S. Lacelle, H. Xia and Y. Zhao, *Langmuir*, 2012, **28**, 16463–16468.
- 116 J. L. Paris, M. V. Cabanas, M. Manzano and M. Vallet-Regí, *ACS Nano*, 2015, **9**, 11023–11033.
- 117 E. J. Kwon and T. G. Lee, *Appl. Surf. Sci.*, 2008, **254**, 4732–4737.
- 118 D. P. Ferris, Y. L. Zhao, N. M. Khashab, H. A. Khatib, J. F. Stoddart and J. I. Zink, *J. Am. Chem. Soc.*, 2009, **131**, 1686–1688.
- 119 D. Tarn, D. P. Ferris, J. C. Barnes, M. W. Ambrogio, J. F. Stoddart and J. I. Zink, *Nanoscale*, 2014, **6**, 3335–3343.
- 120 D. He, X. He, K. Wang, J. Cao and Y. Zhao, *Langmuir*, 2012, **28**, 4003–4008.
- 121 M. A. Azagarsamy, D. L. Alge, S. J. Radhakrishnan, M. W. Tibbitt and K. S. Anseth, *Biomacromolecules*, 2012, **13**, 2219–2224.
- 122 J. Lai, X. Mu, Y. Xu, X. Wu, C. Wu, C. Li, J. Chen and Y. Zhao, *Chem. Commun.*, 2010, **46**, 7370–7372.
- 123 Q. Lin, Q. Huang, C. Li, C. Bao, Z. Liu, F. Li and L. Zhu, *J. Am. Chem. Soc.*, 2010, **132**, 10645–10647.
- 124 N. Z. Knezevic, B. G. Trewyn and V. S. Lin, *Chem. Commun.*, 2011, **47**, 2817–2819.
- 125 J. L. Vivero-Escoto, I. I. Slowing, C.-W. Wu and V. S.-Y. Lin, *J. Am. Chem. Soc.*, 2009, **131**, 3462–3463.
- 126 S. Baek, R. K. Singh, D. Khanal, K. D. Patel, E. J. Lee, K. W. Leong, W. Chrzanowski and H. W. Kim, *Nanoscale*, 2015, **7**, 14191–14216.
- 127 J. Liu, C. Detrembleur, D. Pauw-Gillet, S. Mornet, C. Jérôme and E. Duguet, *Small*, 2015, **11**, 2323–2332.
- 128 H. Li, L.-L. Tan, P. Jia, Q.-L. Li, Y.-L. Sun, J. Zhang, Y.-Q. Ning, J. Yu and Y.-W. Yang, *Chem. Sci.*, 2014, **5**, 2804.
- 129 J. Yang, D. Shen, L. Zhou, W. Li, X. Li, C. Yao, R. Wang, A. M. El-Toni, F. Zhang and D. Zhao, *Chem. Mater.*, 2013, **25**, 3030–3037.
- 130 X. Liu, Q. Ren, F. Fu, R. Zou, Q. Wang, G. Xin, Z. Xiao, X. Huang, Q. Liu and J. Hu, *Dalton Trans.*, 2015, **44**, 10343–10351.
- 131 J. Liu, C. Wang, X. Wang, X. Wang, L. Cheng, Y. Li and Z. Liu, *Adv. Funct. Mater.*, 2015, **25**, 384–392.

- 132 S. He, K. Krippes, S. Ritz, Z. Chen, A. Best, H.-J. Butt, V. Mailänder and S. Wu, *Chem. Commun.*, 2015, **51**, 431–434.
- 133 Q. Zhao, J. Liu, W. Zhu, C. Sun, D. Di, Y. Zhang, P. Wang, Z. Wang and S. Wang, *Acta Biomater.*, 2015, **23**, 147–156.
- 134 Y. Zhang, C. Y. Ang, M. Li, S. Y. Tan, Q. Qu, Z. Luo and Y. Zhao, *ACS Appl. Mater. Interfaces*, 2015, **7**, 18179–18187.
- 135 S. F. Lee, X. M. Zhu, Y. X. Wang, S. H. Xuan, Q. You, W. H. Chan, C. H. Wong, F. Wang, J. C. Yu, C. H. Cheng and K. C. Leung, *ACS Appl. Mater. Interfaces*, 2013, **5**, 1566–1574.
- 136 S. Angelos, Y. W. Yang, N. M. Khashab, J. F. Stoddart and J. I. Zink, *J. Am. Chem. Soc.*, 2009, **131**, 11344–11346.
- 137 X. Chen, A. H. Soeriyadi, X. Lu, S. M. Sagnella, M. Kavallaris and J. J. Gooding, *Adv. Funct. Mater.*, 2014, **24**, 6999–7006.
- 138 Q. Zhao, J. Liu, W. Zhu, C. Sun, D. Di, Y. Zhang, P. Wang, Z. Wang and S. Wang, *Acta Biomater.*, 2015, **23**, 147–156.
- 139 R. Lv, P. Yang, F. He, S. Gai, G. Yang, Y. Dai, Z. Hou and J. Lin, *Biomaterials*, 2015, **63**, 115–127.
- 140 L. Han, C. Tang and C. Yin, *Biomaterials*, 2015, **60**, 42–52.
- 141 I. R. Fernando, D. P. Ferris, M. Frascioni, D. Malin, E. Strelakova, M. D. Yilmaz, M. W. Ambrogio, M. M. Algaradah, M. P. Hong, X. Chen, M. S. Nassar, Y. Y. Botros, V. L. Cryns and J. F. Stoddart, *Nanoscale*, 2015, **7**, 7178–7183.
- 142 S. Zhou, X. Du, F. Cui and X. Zhang, *Small*, 2014, **10**, 980–988.
- 143 D. Xiao, H. Z. Jia, J. Zhang, C. W. Liu, R. X. Zhuo and X. Z. Zhang, *Small*, 2014, **10**, 591–598.
- 144 W. P. Li, P. Y. Liao, C. H. Su and C. S. Yeh, *J. Am. Chem. Soc.*, 2014, **136**, 10062–10075.
- 145 M. Yu, S. Jambhrunkar, P. Thorn, J. Chen, W. Gu and C. Yu, *Nanoscale*, 2013, **5**, 178–183.
- 146 J. Pang, L. Zhao, L. Zhang, Z. Li and Y. Luan, *J. Colloid Interface Sci.*, 2013, **395**, 31–39.
- 147 L. Dai, Q. Zhang, J. Li, X. Shen, C. Mu and K. Cai, *ACS Appl. Mater. Interfaces*, 2015, **7**, 7357–7372.
- 148 X. Ma, Y. Zhao, K. W. Ng and Y. Zhao, *Chemistry*, 2013, **19**, 15593–15603.
- 149 X. Xie, F. Li, H. Zhang, Y. Lu, S. Lian, H. Lin, Y. Gao and L. Jia, *Eur. J. Pharm. Sci.*, 2016, **83**, 28–35.
- 150 Y. Yang, F. Chen, S. Shi, S. Graves, R. Nickles and W. Cai, *J. Nucl. Med.*, 2015, **56**, 117.
- 151 Y. Zhang, J. Guo, X. L. Zhang, D. P. Li, T. T. Zhang, F. F. Gao, N. F. Liu and X. G. Sheng, *Int. J. Pharm.*, 2015, **496**, 1026–1033.
- 152 Y. T. Liao, C. H. Liu, J. Yu and K. C. Wu, *Int. J. Nanomed.*, 2014, **9**, 2767–2778.
- 153 G. Quan, X. Pan, Z. Wang, Q. Wu, G. Li, L. Dian, B. Chen and C. Wu, *J. Nanobiotechnol.*, 2015, **13**, 7.
- 154 P. Zhang, F. Cheng, R. Zhou, J. Cao, J. Li, C. Burda, Q. Min and J. J. Zhu, *Angew. Chem., Int. Ed.*, 2014, **53**, 2371–2375.
- 155 F.-F. Zheng, P.-H. Zhang, Y. Xi, J.-J. Chen, L.-L. Li and J.-J. Zhu, *Anal. Chem.*, 2015, **87**, 11739–11745.
- 156 C. Liu, J. Zheng, L. Deng, C. Ma, J. Li, Y. Li, S. Yang, J. Yang, J. Wang and R. Yang, *ACS Appl. Mater. Interfaces*, 2015, **7**, 11930–11938.
- 157 W. Fang, Z. Wang, S. Zong, H. Chen, D. Zhu, Y. Zhong and Y. Cui, *Biosens. Bioelectron.*, 2014, **57**, 10–15.
- 158 J. Zhang, Z. F. Yuan, Y. Wang, W. H. Chen, G. F. Luo, S. X. Cheng, R. X. Zhuo and X. Z. Zhang, *J. Am. Chem. Soc.*, 2013, **135**, 5068–5073.
- 159 J. Mo, L. He, B. Ma and T. Chen, *ACS Appl. Mater. Interfaces*, 2016, **8**, 6811–6825.
- 160 X. Wu, Z. Han, R. Schur and Z. R. Lu, *Biogeochemistry*, 2016, **16**, 1–42.
- 161 X. Li, M. Wu, L. Pan and J. Shi, *Int. J. Nanomed.*, 2016, **11**, 93.
- 162 R. Chakravarty, S. Goel, H. Hong, F. Chen, H. F. Valdovinos, R. Hernandez, T. E. Barnhart and W. Cai, *Nanomedicine*, 2015, **10**, 1233–1246.
- 163 G.-F. Luo, W.-H. Chen, Y. Liu, J. Zhang, S.-X. Cheng, R.-X. Zhuo and X.-Z. Zhang, *J. Mater. Chem. B*, 2013, **1**, 5723–5732.
- 164 J. J. Hu, L. H. Liu, Z. Y. Li, R. X. Zhuo and X. Z. Zhang, *J. Mater. Chem. B*, 2016, **4**, 1932–1940.
- 165 K. Wang, H. Yao, Y. Meng, Y. Wang, X. Yan and R. Huang, *Acta Biomater.*, 2015, **16**, 196–205.
- 166 J. Ding, J. Yao, J. Xue, R. Li, B. Bao, L. Jiang, J. J. Zhu and Z. He, *ACS Appl. Mater. Interfaces*, 2015, **7**, 18145–18155.
- 167 Y. Chen, X. Wang, T. Liu, D. S. Zhang, Y. Wang, H. Gu and W. Di, *Int. J. Nanomed.*, 2015, **10**, 2579–2594.
- 168 S. Goel, F. Chen, H. Hong, H. F. Valdovinos, R. Hernandez, S. Shi, T. E. Barnhart and W. Cai, *ACS Appl. Mater. Interfaces*, 2014, **6**, 21677–21685.
- 169 F. Chen, H. Hong, Y. Zhang, H. F. Valdovinos, S. Shi, G. S. Kwon, C. P. Theuer, T. E. Barnhart and W. Cai, *ACS Nano*, 2013, **7**, 9027–9039.
- 170 H. Yang, F. Zhao, Y. Li, M. Xu, L. Li, C. Wu, H. Miyoshi and Y. Liu, *Int. J. Nanomed.*, 2013, **8**, 1897–1906.
- 171 L. Pan, J. Liu, Q. He, L. Wang and J. Shi, *Biomaterials*, 2013, **34**, 2719–2730.
- 172 M. Wu, Q. Meng, Y. Chen, Y. Du, L. Zhang, Y. Li, L. Zhang and J. Shi, *Adv. Mater.*, 2015, **27**, 215–222.
- 173 Z. Y. Li, Y. Liu, J. J. Hu, Q. Xu, L. H. Liu, H. Z. Jia, W. H. Chen, Q. Lei, L. Rong and X. Z. Zhang, *ACS Appl. Mater. Interfaces*, 2014, **6**, 14568–14575.
- 174 L. Xiong, X. Du, F. Kleitz and S. Z. Qiao, *Small*, 2015, **11**, 5919–5926.
- 175 Y. Liu, Q. Chen, M. Xu, G. Guan, W. Hu, Y. Liang, X. Zhao, M. Qiao, D. Chen and H. Liu, *Int. J. Nanomed.*, 2015, **10**, 1855.
- 176 L. Pan, J. Liu, Q. He and J. Shi, *Adv. Mater.*, 2014, **26**, 6742–6748.
- 177 Z. Li, K. Dong, S. Huang, E. Ju, Z. Liu, M. Yin, J. Ren and X. Qu, *Adv. Funct. Mater.*, 2014, **24**, 3612–3620.
- 178 D. Neri and R. Bicknell, *Nat. Rev. Cancer*, 2005, **5**, 436–446.
- 179 M. Srinivasarao, C. V. Galliford and P. S. Low, *Nat. Rev. Drug Discovery*, 2015, **14**, 203–219.
- 180 C. P. Tsai, C. Y. Chen, Y. Hung, F. H. Chang and C. Y. Mou, *J. Mater. Chem.*, 2009, **19**, 5737–5743.
- 181 K. Laginha, D. Mumbengegwi and T. Allen, *Biochim. Biophys. Acta, Biomembr.*, 2005, **1711**, 25–32.
- 182 A. Salvati, A. S. Pitek, M. P. Monopoli, K. Prapainop, F. B. Bombelli, D. R. Hristov, P. M. Kelly, C. Aberg, E. Mahon and K. A. Dawson, *Nat. Nanotechnol.*, 2013, **8**, 137–143.
- 183 Q. He and J. Shi, *Adv. Mater.*, 2014, **26**, 391–411.